[
  {
    "Company": "Travere",
    "Candidate": "CHOLBAM",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2014",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2015",
    "PRV Month": "3",
    "Date": "17",
    "TherapeuticArea1": "Gastroenterology",
    "TherapeuticArea2": "",
    "Indication": "Bile acid synthesis disorders",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "Cholic acid",
    "Class1": "Biologic",
    "Class2": "",
    "Class3": "",
    "MOA": "Cholic acid",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Sanofi",
    "Sale Price (USD Millions)": "245",
    "Purchase Month": "5",
    "Purchase Date": "27",
    "Purchase Year": "2015",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Sarepta Therapeutics",
    "Candidate": "EXONDYS 51",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mid",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "9",
    "RPDD Date": "",
    "RPDD Year": "2015",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2016",
    "PRV Month": "10",
    "Date": "17",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "eteplirsen",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "Antisense oligonucleotides",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Gilead",
    "Sale Price (USD Millions)": "125",
    "Purchase Month": "2",
    "Purchase Date": "21",
    "Purchase Year": "2017",
    "Acquisition": "Y",
    "Acquirer": "Gilead",
    "Acquisition Price": "$125,000,000.00",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Sarepta Therapeutics",
    "Candidate": "SRP-9003",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mid",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "9",
    "RPDD Date": "",
    "RPDD Year": "2015",
    "Current Development Stage": "Phase 3",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Limb-Girdle Muscular Dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "bidridistrogene xeboparvovec",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "AAVrh74 vector",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "N",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "AstraZeneca",
    "Candidate": "KOSELUGO",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "UK",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mega",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2016",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2020",
    "PRV Month": "9",
    "Date": "16",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "neurofibromatosis type 1 (NF1-PN)",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "selumetinib",
    "Class1": "Enzyme inhibitor",
    "Class2": "",
    "Class3": "",
    "MOA": "MEK 1/2 inhibitor",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "NA",
    "Purchase Date": "Na",
    "Purchase Year": "NA",
    "Acquisition": "N",
    "Acquirer": "NA",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "9/1/16",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "11/1/18",
    "BLA submission": "3/1/19"
  },
  {
    "Company": "bluebird Bio",
    "Candidate": "Zynteglo",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2016",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2022",
    "PRV Month": "8",
    "Date": "29",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "ÃŸ-thalassemia",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "betibeglogene autotemcel",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "Gene addition",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Bristol Myers Squibb",
    "Sale Price (USD Millions)": "95",
    "Purchase Month": "1",
    "Purchase Date": "5",
    "Purchase Year": "2023",
    "Acquisition": "N",
    "Acquirer": "NA",
    "Acquisition Price": "NA",
    "Acq month": "NA",
    "Acq date": "NA",
    "Acq year": "NA",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "2/1/14",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "4/1/17",
    "BLA submission": "7/1/21"
  },
  {
    "Company": "Day One",
    "Candidate": "OJEMDA",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2016",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2024",
    "PRV Month": "4",
    "Date": "23",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "Tovorafenib",
    "Class1": "Enzyme inhibitor",
    "Class2": "",
    "Class3": "",
    "MOA": "kinase inhibitors",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Undisclosed",
    "Sale Price (USD Millions)": "108",
    "Purchase Month": "5",
    "Purchase Date": "30",
    "Purchase Year": "2024",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Leadiant Bioscience",
    "Candidate": "REVCOVI",
    "CompanyWebsite": "https://leadiant.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2016",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2018",
    "PRV Month": "10",
    "Date": "25",
    "TherapeuticArea1": "Immunology",
    "TherapeuticArea2": "",
    "Indication": "Adenosine deaminase deficiency-SCID",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "elapegademase-lvlr",
    "Class1": "Enzyme Replacement",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Novimmune",
    "Candidate": "Gamifant",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "CH",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2016",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2018",
    "PRV Month": "12",
    "Date": "13",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "Hemophagocytic lymphohistiocytosis",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "Emapalumab",
    "Class1": "Immunosuppresant",
    "Class2": "",
    "Class3": "",
    "MOA": "Interferon gamma blocking antibody",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "AstraZeneca",
    "Sale Price (USD Millions)": "95",
    "Purchase Month": "8",
    "Purchase Date": "22",
    "Purchase Year": "2019",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Vertex",
    "Candidate": "SYMDEKO",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2016",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2019",
    "PRV Month": "3",
    "Date": "29",
    "TherapeuticArea1": "Pulmonology",
    "TherapeuticArea2": "",
    "Indication": "Cystic fibrosis",
    "Approved Drug": "Y",
    "FDA-Approved Therapy Prior to 2012": "TOBI; Cayston; Pulomzyme",
    "Active Ingredient": "tezacaftor/ivacaftor",
    "Class1": "CFTR modulators",
    "Class2": "",
    "Class3": "",
    "MOA": "Cystic fibrosis transmembrane conductance regulator",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "NA",
    "Purchase Date": "Na",
    "Purchase Year": "NA",
    "Acquisition": "N",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Polaryx Therapeutics",
    "Candidate": "PLX-200",
    "CompanyWebsite": "https://polaryx.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Seed",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "Undisclosed",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "Majority shareholder is Mstone Healthcare",
    "FundingNotesLink": "",
    "Commercial stage": "Pivotal stage",
    "RPDD Month": "8",
    "RPDD Date": "7",
    "RPDD Year": "2017",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL)",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Polaryx Therapeutics",
    "Candidate": "PLX-200",
    "CompanyWebsite": "https://polaryx.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Seed",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "Undisclosed",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "Majority shareholder is Mstone Healthcare",
    "FundingNotesLink": "",
    "Commercial stage": "Pivotal stage",
    "RPDD Month": "8",
    "RPDD Date": "7",
    "RPDD Year": "2017",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Batten Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Abeona Therapeutics",
    "Candidate": "ABO-202",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Micro",
    "Headcount": "",
    "MarketCapRange": "100-250M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2018",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 1/2",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Batten Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Albireo AB",
    "Candidate": "BYLVAY",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "SE",
    "Public/Private": "Acquired",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "6",
    "RPDD Date": "",
    "RPDD Year": "2018",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2022",
    "PRV Month": "10",
    "Date": "7",
    "TherapeuticArea1": "Hepatology",
    "TherapeuticArea2": "",
    "Indication": "progressive familial intrahepatic cholestasis",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "odevixibat",
    "Class1": "Enzyme inhibitor",
    "Class2": "",
    "Class3": "",
    "MOA": "Ileal bile acid transporter (IBAT) inhibitor",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Undisclosed",
    "Sale Price (USD Millions)": "105",
    "Purchase Month": "3",
    "Purchase Date": "16",
    "Purchase Year": "2017",
    "Acquisition": "Y",
    "Acquirer": "Ipsen",
    "Acquisition Price": "$952,200,000.00",
    "Acq month": "1",
    "Acq date": "9",
    "Acq year": "2023",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "10/1/18",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "8/1/20",
    "BLA submission": "1/1/21"
  },
  {
    "Company": "Amryt Pharmaceuticals",
    "Candidate": "FILSUVEZ",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "IE",
    "Public/Private": "Acquired",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2018",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2024",
    "PRV Month": "1",
    "Date": "11",
    "TherapeuticArea1": "Dermatology",
    "TherapeuticArea2": "",
    "Indication": "Dystrophic Epidermolysis Bullosa",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "birch triterpenes",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "COL7A1 gene via viral vector",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "Y",
    "Acquirer": "Chiesi",
    "Acquisition Price": "$1,705,000,000.00",
    "Acq month": "1",
    "Acq date": "9",
    "Acq year": "2023",
    "Acq notes": "Under the deal, Chiesi will pay $1.25 billion upfront for Amryt plus up to $225 million more if Amryt's rare skin disease drug Filsuvez can gain an FDA approval and wins a priority review voucher as a result of that nod.",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "AUG Therapeutics",
    "Candidate": "AVTX-801 (ex-CERC-801)",
    "CompanyWebsite": "",
    "Company 2": "Avalo Therapeutics, ex Cerecor, ex Ichorion Therapeutics",
    "Company 2 Context": "Ex",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2018",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 2",
    "CurrentStudyStatus": "Not Yet Recruiting",
    "Current Study": "https://clinicaltrials.gov/study/NCT05402332?intr=AVTX-801&rank=1",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "2024-10-24",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Phosphoglucomutase 1 (PGM1) Deficiency",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "BioMarin",
    "Candidate": "Voxzogo",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mid",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2018",
    "Current Development Stage": "Phase 2",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2021",
    "PRV Month": "9",
    "Date": "6",
    "TherapeuticArea1": "Orthopedics",
    "TherapeuticArea2": "",
    "Indication": "Achondroplasia",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "Analogs & derivatives",
    "Class2": "",
    "Class3": "",
    "MOA": "CNP analogs",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Undisclosed",
    "Sale Price (USD Millions)": "110",
    "Purchase Month": "2",
    "Purchase Date": "9",
    "Purchase Year": "2022",
    "Acquisition": "N",
    "Acquirer": "",
    "Acquisition Price": "$100,000,000.00",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "11/1/15",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "10/1/19",
    "BLA submission": "1/1/21"
  },
  {
    "Company": "Castle Creek Pharmaceuticals",
    "Candidate": "Diacerin",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mid",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2018",
    "Current Development Stage": "Phase 2",
    "PRV Status": "Phase 3",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Epidermolysis Bullosa Simplex",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Cellectar Biosciences",
    "Candidate": "CLR-131",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Micro",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Pivotal stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2018",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 1",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Rhabdomyosarcoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Cellectar Biosciences",
    "Candidate": "CLR-131",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Micro",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Pivotal stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2018",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 1",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Osteosarcoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Cellectar Biosciences",
    "Candidate": "CLR-131",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Micro",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Pivotal stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2018",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 1",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Neuroblastoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Cellectar Biosciences",
    "Candidate": "CLR-131",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Micro",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Pivotal stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2018",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 1",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Ewing's Sarcoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Chiesi Farmaceutici S.p.A.",
    "Candidate": "LAMZEDE",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "IT",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Mid",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2018",
    "Current Development Stage": "Phase 3",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2023",
    "PRV Month": "3",
    "Date": "16",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "non-central nervous system manifestations of alpha-mannosidosis",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "velmanase alfa-tycv",
    "Class1": "Enzyme Replacement",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "NA",
    "Purchase Date": "Na",
    "Purchase Year": "NA",
    "Acquisition": "N",
    "Acquirer": "NA",
    "Acquisition Price": "NA",
    "Acq month": "NA",
    "Acq date": "Na",
    "Acq year": "NA",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "10/1/13",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "3/1/16",
    "BLA submission": "12/1/17"
  },
  {
    "Company": "Immedica",
    "Candidate": "Pegzilarginase",
    "CompanyWebsite": "https://www.immedica.com",
    "Company 2": "Aeglea Therapeutics",
    "Company 2 Context": "Acquired from",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "SE",
    "Public/Private": "Acquired",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2018",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "Filed",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Hyperargininaemia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "Y",
    "Acquirer": "KKR",
    "Acquisition Price": "Undisclosed",
    "Acq month": "9",
    "Acq date": "20",
    "Acq year": "2024",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "IntraBio",
    "Candidate": "AQNEURSA",
    "CompanyWebsite": "https://intrabio.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Series C",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "$15,000,000.00",
    "LastFundraiseType": "C",
    "Funding type": "",
    "FundraiseDate": "4/12/2023",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "4",
    "RPDD Date": "12",
    "RPDD Year": "2018",
    "Current Development Stage": "Phase 2",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2024",
    "PRV Month": "9",
    "Date": "25",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Niemann-Pick disease type C",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "Levacetylleucine",
    "Class1": "Acetamides",
    "Class2": "",
    "Class3": "",
    "MOA": "Calcium channel modulators",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "IntraBio",
    "Candidate": "IB1000s",
    "CompanyWebsite": "https://intrabio.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Series C",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "$15,000,000.00",
    "LastFundraiseType": "C",
    "Funding type": "",
    "FundraiseDate": "4/12/2023",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2018",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 2",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "GM2 Gangliosidosis (Tay-Sachs & Sandhoff)",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Krystal Biotech",
    "Candidate": "VYJUVEK",
    "CompanyWebsite": "https://www.krystalbio.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "1-10B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2018",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2023",
    "PRV Month": "6",
    "Date": "6",
    "TherapeuticArea1": "Dermatology",
    "TherapeuticArea2": "",
    "Indication": "Dystrophic Epidermolysis Bullosa",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "beremagene geperpavec-svdt",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Undisclosed",
    "Sale Price (USD Millions)": "100",
    "Purchase Month": "8",
    "Purchase Date": "21",
    "Purchase Year": "2023",
    "Acquisition": "N",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Krystal Biotech",
    "Candidate": "Inetagugene geperpavec (KB105)",
    "CompanyWebsite": "https://www.krystalbio.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "1-10B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2018",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 2",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "TGM-1-Deficient Autosomal Recessive Congenital Ichthyosis",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "MeiraGTx",
    "Candidate": "A002",
    "CompanyWebsite": "https://meiragtx.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "UK",
    "Public/Private": "",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "500M-1B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2018",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "Phase 2",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Achromatopsia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Moderna Therapeutics",
    "Candidate": "mRNA-3704",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "10--50B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2018",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 2",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Methylmalonic Acidemia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Modis Therapeutics",
    "Candidate": "MT1621",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Acquired",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "10",
    "RPDD Date": "2",
    "RPDD Year": "2018",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Thymidine Kinase 2 deficiency",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "Y",
    "Acquirer": "Zogenix",
    "Acquisition Price": "$250,000,000.00",
    "Acq month": "8",
    "Acq date": "26",
    "Acq year": "2019",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Modus Therapeutics",
    "Candidate": "sevuparin",
    "CompanyWebsite": "",
    "Company 2": "Ergomed",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "SE",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "0-10M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "4",
    "RPDD Date": "19",
    "RPDD Year": "2018",
    "Current Development Stage": "Phase 2",
    "PRV Status": "Phase 2",
    "CurrentStudyStatus": "",
    "Current Study": "Active",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "7/5/2019",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "Sickle Cell Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Novartis",
    "Candidate": "Kymriah",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "CH",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mega",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2018",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2017",
    "PRV Month": "9",
    "Date": "11",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Acute lymphoblastic leukemia",
    "Approved Drug": "Y",
    "FDA-Approved Therapy Prior to 2012": "Arranon; Clolar",
    "Active Ingredient": "tisagenlecleucel",
    "Class1": "Immunotherapy",
    "Class2": "",
    "Class3": "",
    "MOA": "CAR T",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "N",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Novo Nordisk",
    "Candidate": "ALHEMO",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "DE",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "10",
    "RPDD Date": "22",
    "RPDD Year": "2018",
    "Current Development Stage": "Phase 2",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2024",
    "PRV Month": "12",
    "Date": "20",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "Hemophilia Type A and B",
    "Approved Drug": "Y",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "concizumab-mtci",
    "Class1": "Antibody",
    "Class2": "Monoclonal antibodies",
    "Class3": "",
    "MOA": "SPINT2 Inhibitor",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Orchard Therapeutics",
    "Candidate": "OTL-103",
    "CompanyWebsite": "https://www.orchard-tx.com/",
    "Company 2": "Kyowa Kirin",
    "Company 2 Context": "Parent",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "JP",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2018",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "Phase 3",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Wiskott Aldrich Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Rocket Pharmaceuticals",
    "Candidate": "Mozafancogene autotemcel (RP-L102)",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mid",
    "Headcount": "",
    "MarketCapRange": "500M-1B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2018",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "Filed",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Fanconi Anemia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Sarepta Therapeutics",
    "Candidate": "AMONDYS 45",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mid",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2018",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2021",
    "PRV Month": "3",
    "Date": "12",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "casimersen",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "Antisense oligonucleotides",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "N",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "Y",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Sarepta Therapeutics",
    "Candidate": "VYONDYS 53",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mid",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2018",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2020",
    "PRV Month": "1",
    "Date": "23",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "golodirsen",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "Exon-skipping",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "Y",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Sarepta Therapeutics",
    "Candidate": "SRP-9003 (bidridistrogene xeboparvovec, MYO-101)",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2018",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 3",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Limb-Girdle Muscular Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Spyre Therapeutics",
    "Candidate": "Pegzilarginase",
    "CompanyWebsite": "",
    "Company 2": "Immedica Pharma AB",
    "Company 2 Context": "Sold candidate to",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "10",
    "RPDD Date": "1",
    "RPDD Year": "2018",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "Phase 3",
    "CurrentStudyStatus": "Recruiting",
    "Current Study": "https://clinicaltrials.gov/study/NCT06582524?intr=Pegzilarginase&rank=1",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "2025-03-25",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Arginase 1 Deficiency",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "Y",
    "AssetAcquirer": "Immedica Pharma AB",
    "AssetAcqPrice": "$100,000,000.00",
    "AssetAcqDate": "7/27/2023",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Vertex",
    "Candidate": "CASGEVY",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2018",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2024",
    "PRV Month": "1",
    "Date": "9",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "Sickle Cell Disease (SCD)",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "exagamglogene autotemcel",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "Gene editing",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "NA",
    "Purchase Date": "Na",
    "Purchase Year": "NA",
    "Acquisition": "N",
    "Acquirer": "NA",
    "Acquisition Price": "NA",
    "Acq month": "NA",
    "Acq date": "NA",
    "Acq year": "NA",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Wave Life Sciences",
    "Candidate": "WVE-210201",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "8",
    "RPDD Date": "16",
    "RPDD Year": "2018",
    "Current Development Stage": "Phase 1",
    "PRV Status": "Terminated",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "1/9/2020",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Wave Life Sciences",
    "Candidate": "Suvodirsen (WVE-210201)",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "",
    "MarketCapRPD": "",
    "MarketCap": "",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2018",
    "Current Development Stage": "Phase 1",
    "PRV Status": "Terminated",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "AlaMab Therapeutics",
    "Candidate": "ALMB-0168",
    "CompanyWebsite": "https://alamab.com/",
    "Company 2": "CSPC Pharmaceuticals",
    "Company 2 Context": "Ex",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Series A",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "$11,800,000.00",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "8/2/2017",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2019",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 1",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Osteosarcoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "AmMax Bio",
    "Candidate": "LM-030 (BPR277)",
    "CompanyWebsite": "https://www.ammaxbio.com",
    "Company 2": "Novartis",
    "Company 2 Context": "Licensed from",
    "Company 3": "LifeMax Laboratories",
    "Company 3 Context": "Ex",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2019",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 2/3",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Netherton Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Anavex Life Sciences",
    "Candidate": "blarcamesine",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mid",
    "Headcount": "",
    "MarketCapRange": "500M-1B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2019",
    "Current Development Stage": "Phase 2",
    "PRV Status": "Phase 2",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Rett Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "AstraZeneca (ex Alexion, ex LogicBio Therapeutics)",
    "Candidate": "LB-001",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mega",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2019",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Terminated following Phase 1/2",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Methylmalonic Acidemia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Auregen Biotherapeutics",
    "Candidate": "AUR-201",
    "CompanyWebsite": "https://www.auregen.bio/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Acquired",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2019",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 1/2",
    "CurrentStudyStatus": "Recruiting",
    "Current Study": "https://clinicaltrials.gov/study/NCT06078566?intr=AUR-201&rank=2",
    "EstimatedStudyCompletion": "2025-05-01",
    "LastStatusUpdate": "2024-02-02",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Otolaryngology",
    "TherapeuticArea2": "",
    "Indication": "Microtia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Biogen",
    "Candidate": "SPINRAZA",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2019",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2017",
    "PRV Month": "3",
    "Date": "6",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Spinal muscular atrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "Gene therapy",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "Antisense oligonucleotides",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "N",
    "Acquirer": "NA",
    "Acquisition Price": "NA",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "1/1/13",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "12/1/15",
    "BLA submission": "7/1/16"
  },
  {
    "Company": "bluebird Bio",
    "Candidate": "SKYSONA",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Acquired",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2019",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2022",
    "PRV Month": "10",
    "Date": "7",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Cerebral adrenoleukodystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "elivaldogene autotemcel",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "argenX",
    "Sale Price (USD Millions)": "102",
    "Purchase Month": "11",
    "Purchase Date": "30",
    "Purchase Year": "2022",
    "Acquisition": "Y",
    "Acquirer": "Carlyle, SK Capital",
    "Acquisition Price": "$29,000,000.00",
    "Acq month": "2",
    "Acq date": "21",
    "Acq year": "2025",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "3/1/16",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "1/1/20",
    "BLA submission": "4/1/21"
  },
  {
    "Company": "Denali Therapeutics",
    "Candidate": "DNL310",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2019",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 1/2",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Mucopolysaccharidosis Type II",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Eiger",
    "Candidate": "ZOKINVY",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2019",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2020",
    "PRV Month": "12",
    "Date": "17",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Hutchinson-Gilford Progeria Syndrome (HGPS)",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "lonafarnib",
    "Class1": "Enzyme inhibitor",
    "Class2": "",
    "Class3": "",
    "MOA": "Protein farnesyltransferase inhibitor",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "AbbVie",
    "Sale Price (USD Millions)": "95",
    "Purchase Month": "11",
    "Purchase Date": "23",
    "Purchase Year": "2020",
    "Acquisition": "N",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "Progeria Research Foundation receives 50% under Collaboration Agreement",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Enzyvant",
    "Candidate": "RVT-801",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "JP",
    "Public/Private": "Acquired",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2019",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Licensed to Aceragen (bankrupt)",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Farber Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Inventiva Pharma",
    "Candidate": "Odiparcil",
    "CompanyWebsite": "https://inventivapharma.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "FR",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mid",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Cllinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2019",
    "Current Development Stage": "Phase 2a",
    "PRV Status": "deprioritized",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Mucopolysaccharidosis VI",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Laboratoires ThÃ©a",
    "Candidate": "sepofarsen",
    "CompanyWebsite": "",
    "Company 2": "ProQR Therapeutics",
    "Company 2 Context": "Licensed from",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "NL",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "1-10B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "2/4/2025",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2019",
    "Current Development Stage": "Phase 2/3",
    "PRV Status": "Phase 3",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Leber Congenital Amaurosis 10",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Larimar Therapeutics",
    "Candidate": "Nomlabofusp (CTI-1601)",
    "CompanyWebsite": "https://larimartx.com/",
    "Company 2": "Chondrial Therapeutics",
    "Company 2 Context": "Merged",
    "Company 3": "Zafgen",
    "Company 3 Context": "Merged",
    "COUNTRY": "US",
    "Public/Private": "",
    "MarketCapRPD": "",
    "MarketCap": "",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2019",
    "Current Development Stage": "Phase 1",
    "PRV Status": "Phase 2",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Friedreich Ataxia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Marathon Pharmaceuticals",
    "Candidate": "EMFLAZA",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Acquired",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2019",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2017",
    "PRV Month": "2",
    "Date": "10",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "deflazacort",
    "Class1": "Immunosuppresant",
    "Class2": "",
    "Class3": "",
    "MOA": "Anti-infllamatory corticosteroid",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "Y",
    "Acquirer": "PTC Therapeutics",
    "Acquisition Price": "$190,000,000.00",
    "Acq month": "3",
    "Acq date": "16",
    "Acq year": "2017",
    "Acq notes": "Sold off Emflaza",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Moderna Therapeutics",
    "Candidate": "mRNA-3927",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "10--50B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2019",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 2",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Propionic Acidemia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Newron Pharmaceuticals",
    "Candidate": "sarizotan",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "IT",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Micro",
    "Headcount": "",
    "MarketCapRange": "100-250M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2019",
    "Current Development Stage": "Phase 3",
    "PRV Status": "discontinued",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Rett Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "NS Pharma",
    "Candidate": "VILTEPSO",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "JP",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2019",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2020",
    "PRV Month": "9",
    "Date": "4",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "viltolarsen",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "Antisense oligonucleotides",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "N",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Oncotelic (ex Mateon Therapeutics)",
    "Candidate": "OT-101",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "",
    "MarketCapRPD": "",
    "MarketCap": "",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2019",
    "Current Development Stage": "Preclinical",
    "PRV Status": "preclinical",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Diffuse Intrinsic Pontine Glioma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "PrintBio (ex 3DBio Therapeutics)",
    "Candidate": "AuriNovo",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "Small",
    "MarketCap": "",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2019",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 1",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Microtia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "REGENXBIO",
    "Candidate": "RGX-181",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "",
    "MarketCapRPD": "",
    "MarketCap": "",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2019",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Terminated",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Batten Disease (CLN2)",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Rocket Pharmaceuticals",
    "Candidate": "RP-L401",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "",
    "MarketCapRPD": "",
    "MarketCap": "",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2019",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Returned to academic collaborators",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Infantile Malignant Osteopetrosis",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Salarius Pharmaceuticals",
    "Candidate": "seclidemstat",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "",
    "MarketCapRPD": "",
    "MarketCap": "",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2019",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "Phase 2",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Ewing's Sarcoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Ultragenyx",
    "Candidate": "DOJOLVI (USX007, triheptanoin)",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "",
    "MarketCapRPD": "",
    "MarketCap": "",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2019",
    "Current Development Stage": "Phase 2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Long Chain Fatty Acid Oxidation Disorders",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "2020",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Ultragenyx (licensed from GeneTx)",
    "Candidate": "GTX-102",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "",
    "MarketCapRPD": "",
    "MarketCap": "",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2019",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 3",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Angelman Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Vertex",
    "Candidate": "TRIKAFTA",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2019",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2020",
    "PRV Month": "9",
    "Date": "15",
    "TherapeuticArea1": "Pulmonology",
    "TherapeuticArea2": "",
    "Indication": "Cystic fibrosis",
    "Approved Drug": "Y",
    "FDA-Approved Therapy Prior to 2012": "TOBI; Cayston; Pulomzyme",
    "Active Ingredient": "elexacaftor/tezacaftor/ivacaftor",
    "Class1": "Enzyme inhibitor",
    "Class2": "",
    "Class3": "",
    "MOA": "CFTR modulators",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "NA",
    "Purchase Date": "Na",
    "Purchase Year": "NA",
    "Acquisition": "N",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Xenon Pharmaceuticals",
    "Candidate": "XEN007",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "CA",
    "Public/Private": "",
    "MarketCapRPD": "",
    "MarketCap": "",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2019",
    "Current Development Stage": "Phase 1",
    "PRV Status": "Terminated",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Alternating Hemiplegia of Childhood",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Y-mAbs Therapeutics",
    "Candidate": "GD2-GD3 Vaccine",
    "CompanyWebsite": "https://ymabs.com/",
    "Company 2": "MabVax",
    "Company 2 Context": "Licensed from",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2019",
    "Current Development Stage": "Phase 2",
    "PRV Status": "Phase 2",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Neuroblastoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Zealand Pharma",
    "Candidate": "dasiglucagon",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "NL",
    "Public/Private": "",
    "MarketCapRPD": "",
    "MarketCap": "",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2019",
    "Current Development Stage": "Phase 3",
    "PRV Status": "Currently filed",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "",
    "TherapeuticArea2": "",
    "Indication": "Congenital Hyperinsulinism",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Aardvark Therapeutics",
    "Candidate": "ARD-101",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Micro",
    "Headcount": "",
    "MarketCapRange": "100-250M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 2",
    "PRV Status": "Phase 3",
    "CurrentStudyStatus": "Recruiting",
    "Current Study": "https://clinicaltrials.gov/study/NCT06828861?intr=ARD-101&rank=1",
    "EstimatedStudyCompletion": "2026-04",
    "LastStatusUpdate": "2025-03-21",
    "StatusNote": "",
    "StatusNoteLink": "https://clinicaltrials.gov/study/NCT06828861?intr=ARD-101&rank=1",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Endocrinology",
    "TherapeuticArea2": "Genetic",
    "Indication": "Prader-Willi Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "Anti-inflammatories",
    "Class2": "Obesity",
    "Class3": "Small molecules",
    "MOA": "G protein-coupled receptor agonists",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Acadia Pharmaceuticals",
    "Candidate": "DAYBUE",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "1-5B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "3",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2023",
    "PRV Month": "3",
    "Date": "10",
    "TherapeuticArea1": "Hepatology",
    "TherapeuticArea2": "",
    "Indication": "Rett Syndrome",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "trofinetide",
    "Class1": "Analogs & derivatives",
    "Class2": "",
    "Class3": "",
    "MOA": "Glycine-proline-glutamate analog",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Undisclosed",
    "Sale Price (USD Millions)": "150",
    "Purchase Month": "11",
    "Purchase Date": "6",
    "Purchase Year": "2024",
    "Acquisition": "N",
    "Acquirer": "NA",
    "Acquisition Price": "NA",
    "Acq month": "NA",
    "Acq date": "NA",
    "Acq year": "NA",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "4/1/21",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "2/1/22",
    "BLA submission": "8/1/22"
  },
  {
    "Company": "Alexion",
    "Candidate": "STRENSIQ",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2015",
    "PRV Month": "4",
    "Date": "7",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Hypophosphatasia (HPP)",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "asfotase alfa",
    "Class1": "Enzyme Replacement",
    "Class2": "",
    "Class3": "",
    "MOA": "recombinant glycoprotein that contains the catalytic domain (the active site) of TNSALP",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "N",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "11/1/10",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "3/1/13",
    "BLA submission": "6/1/14"
  },
  {
    "Company": "Alexion",
    "Candidate": "KANUMA",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2019",
    "PRV Month": "7",
    "Date": "1",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Lysosomal Acid Lipase deficiency",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "Sebelipase alfa",
    "Class1": "Enzyme Replacement",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "Y",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "Y",
    "Acquirer": "AstraZeneca",
    "Acquisition Price": "$39,000,000,000.00",
    "Acq month": "12",
    "Acq date": "12",
    "Acq year": "2020",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "7/1/12",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "5/1/14",
    "BLA submission": "9/1/15"
  },
  {
    "Company": "Allterum Therapeutics",
    "Candidate": "4A10",
    "CompanyWebsite": "https://allterum.com//",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Grant-Supported",
    "Headcount": "1-10",
    "MarketCapRange": "",
    "TotalFunding": "$16,700,000.00",
    "LastFundraise": "$12,000,000.00",
    "LastFundraiseType": "CPRIT Grant",
    "Funding type": "Government grant",
    "FundraiseDate": "4/8/2024",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "10",
    "RPDD Date": "6",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 1/2a",
    "CurrentStudyStatus": "Initiating",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "Acute Lymphoblastic Leukemia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Alnylam Pharmaceuticals",
    "Candidate": "OXLUMO",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mid",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2021",
    "PRV Month": "2",
    "Date": "16",
    "TherapeuticArea1": "Nephrology",
    "TherapeuticArea2": "",
    "Indication": "Primary hyperoxaluria type 1",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "lumasiran",
    "Class1": "RNA interference",
    "Class2": "",
    "Class3": "",
    "MOA": "Silences the HAO1",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "NA",
    "Purchase Date": "Na",
    "Purchase Year": "NA",
    "Acquisition": "N",
    "Acquirer": "NA",
    "Acquisition Price": "NA",
    "Acq month": "NA",
    "Acq date": "NA",
    "Acq year": "NA",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "5/1/17",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "7/1/19",
    "BLA submission": "10/1/20"
  },
  {
    "Company": "Amicus Therapeutics",
    "Candidate": "AAV9 CLN3",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "Terminated",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "CLN3",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Amicus Therapeutics",
    "Candidate": "scAAV9.CB.CLN6",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "Terminated",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "CLN6",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "AmideBio",
    "Candidate": "AB-G023",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "$1,930,000.00",
    "LastFundraiseType": "NIDDK Grant",
    "Funding type": "Government grant",
    "FundraiseDate": "9/11/2024",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 2",
    "CurrentStudyStatus": "Initiating",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Endocrinology",
    "TherapeuticArea2": "",
    "Indication": "Congenital Hyperinsulinism",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "AMO Pharma",
    "Candidate": "AMO-02",
    "CompanyWebsite": "https://www.amo-pharma.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "UK",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "$35,000,000.00",
    "LastFundraiseType": "B",
    "Funding type": "Private equity",
    "FundraiseDate": "1/8/2020",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Pivotal stage",
    "RPDD Month": "11",
    "RPDD Date": "9",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 2",
    "PRV Status": "Phase 2/3",
    "CurrentStudyStatus": "Recruiting",
    "Current Study": "https://clinicaltrials.gov/study/NCT05004129?spons=AMO%20Pharma%20Limited&rank=1",
    "EstimatedStudyCompletion": "2025-03-28",
    "LastStatusUpdate": "2023-11-05",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Congenital Myotonic Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Anida Pharma",
    "Candidate": "AP-001",
    "CompanyWebsite": "https://anidapharma.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "Undisclosed",
    "LastFundraiseType": "Seed",
    "Funding type": "Undisclosed",
    "FundraiseDate": "12/21/2020",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "9",
    "RPDD Date": "1",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Unknown",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "",
    "Indication": "Retinopathy of Prematurity",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Aruvant Sciences",
    "Candidate": "ARU-1801",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "Terminated",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "Sickle Cell Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Avalo Therapeutics",
    "Candidate": "AVTX-006 / ex-CERC-006",
    "CompanyWebsite": "",
    "Company 2": "Cerecor",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "50-100M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "8",
    "RPDD Date": "4",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Terminated",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Lymphatic Malformations",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Axovia Therapeutics",
    "Candidate": "AXV101",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "UK",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "$2,000,000.00",
    "LastFundraiseType": "A Rarce Against Blindness Grant",
    "Funding type": "Advocacy grant",
    "FundraiseDate": "2/5/2025",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Preclinical",
    "CurrentStudyStatus": "Positive results announced",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "2024-10-24",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Bardet-Biedl Syndrome 1",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Azitra",
    "Candidate": "ATR-12",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 1",
    "CurrentStudyStatus": "Active, not recruiting",
    "Current Study": "https://clinicaltrials.gov/study/NCT05153434?intr=ARD-101&rank=3",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "2025-01-20",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Dermatology",
    "TherapeuticArea2": "",
    "Indication": "Netherton Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Bexion Pharmaceuticals",
    "Candidate": "BXQ-350",
    "CompanyWebsite": "https://www.bexionpharma.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "$1,430,000.00",
    "LastFundraiseType": "Michael J. Fox Foundation Grant",
    "Funding type": "Advocacy grant",
    "FundraiseDate": "11/14/2024",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1",
    "PRV Status": "Phase 1 ",
    "CurrentStudyStatus": "Terminated",
    "Current Study": "https://www.clinicaltrials.gov/study/NCT04404569",
    "EstimatedStudyCompletion": "2024-09-23",
    "LastStatusUpdate": "2024-12-18",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Diffuse Midline Glioma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "bluebird Bio",
    "Candidate": "LYFGENIA",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Acquired",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "Terminated",
    "CurrentStudyStatus": "Terminated",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "Sickle Cell Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "Y",
    "Acquirer": "Carlyle, SK Capital",
    "Acquisition Price": "$29,000,000.00",
    "Acq month": "2",
    "Acq date": "21",
    "Acq year": "2025",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "CalciMedica",
    "Candidate": "GB-501",
    "CompanyWebsite": "",
    "Company 2": "Graybug - acquired from RainBIO",
    "Company 2 Context": "Merger",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "10-25M",
    "TotalFunding": "",
    "LastFundraise": "$10,000,000.00",
    "LastFundraiseType": "Credit facility",
    "Funding type": "Debt",
    "FundraiseDate": "3/5/2025",
    "FundingNotes": "The credit agreement, which has a term of 3.5 years, includes an initial tranche of $10 million fully funded at close and additional tranches of up to $22.5 million available to the Company subject to certain milestones. ",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Preclinical",
    "CurrentStudyStatus": "Unknown",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "",
    "Indication": "Mucopolysaccharidosis Type 1",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Cartesian Therapeutics",
    "Candidate": "MMA-101",
    "CompanyWebsite": "https://www.cartesiantherapeutics.com/",
    "Company 2": "Selecta Biosciences",
    "Company 2 Context": "Acquisition",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "250-500M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 2",
    "CurrentStudyStatus": "Withdrawn",
    "Current Study": "https://clinicaltrials.gov/study/NCT05778877",
    "EstimatedStudyCompletion": "2029-08",
    "LastStatusUpdate": "2024-09-23",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Methylmalonic Acidemia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Cerecin Neurosciences",
    "Candidate": "tricaprilin",
    "CompanyWebsite": "https://cerecin.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "$77,300,000.00",
    "LastFundraise": "$40,000,000.00",
    "LastFundraiseType": "B",
    "Funding type": "Venture",
    "FundraiseDate": "9/28/2022",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 3",
    "CurrentStudyStatus": "Initiating ",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Infantile Spasms",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Chimerix",
    "Candidate": "dordaviprone (ONC201)",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Acquired",
    "MarketCapRPD": "",
    "MarketCap": "Mid",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1",
    "PRV Status": "Phase 3",
    "CurrentStudyStatus": "Recruiting",
    "Current Study": "https://clinicaltrials.gov/study/NCT05580562?intr=dordaviprone%20(ONC201)&rank=3",
    "EstimatedStudyCompletion": "2026-08",
    "LastStatusUpdate": "2025-02-28",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "H3 K27M-mutant Diffuse Glioma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "Y",
    "Acquirer": "Jazz Pharmaceuticals",
    "Acquisition Price": "$935,000,000.00",
    "Acq month": "3",
    "Acq date": "5",
    "Acq year": "2025",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Clarity Pharmaceuticals",
    "Candidate": "67Cu-SARTATEâ„¢",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "AU",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "250-500M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 1/2a",
    "CurrentStudyStatus": "Recruiting",
    "Current Study": "https://clinicaltrials.gov/study/NCT04023331?intr=67Cu-SARTATE%E2%84%A2&rank=1",
    "EstimatedStudyCompletion": "2028-12",
    "LastStatusUpdate": "2024-07-05",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Neuroblastoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Crinetics Pharmaceuticals",
    "Candidate": "CRN04777",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "1-10B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1",
    "PRV Status": "Terminated",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "6/30/2023",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Endocrinology",
    "TherapeuticArea2": "",
    "Indication": "Congenital Hyperinsulinism",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Curtana Pharmaceuticals",
    "Candidate": "CT-179",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "$7,600,000.00",
    "LastFundraiseType": "CPRIT Grant",
    "Funding type": "Government grant",
    "FundraiseDate": "8/21/2014",
    "FundingNotes": "The company has raised an undisclosed amount of venture funding from Current investors include Thynk Capital, angelMD,\nBiosense Global, DEFTA Partners, and other anonymous investors.",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Preclinical",
    "CurrentStudyStatus": "Ongoing",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "9/20/2023",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Medulloblastoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Cyprium Therapeutics",
    "Candidate": "CUTX-101",
    "CompanyWebsite": "",
    "Company 2": "Fortress Biotech",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "$4,100,000.00",
    "LastFundraiseType": "NINDS grant",
    "Funding type": "Government grant",
    "FundraiseDate": "3/4/2024",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Pivotal stage",
    "RPDD Month": "1",
    "RPDD Date": "16",
    "RPDD Year": "2020",
    "Current Development Stage": "Asset sold",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Menkes Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "Y",
    "AssetAcquirer": "Cyprium Therapeutics",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Dynacure",
    "Candidate": "DYN101",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "FR",
    "Public/Private": "Merger",
    "MarketCapRPD": "",
    "MarketCap": "Mid",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "$55,000,000.00",
    "LastFundraiseType": "C ",
    "Funding type": "Venture",
    "FundraiseDate": "4/1/2020",
    "FundingNotes": "Merged with Flamingo ",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "Terminated",
    "CurrentStudyStatus": "",
    "Current Study": "https://www.fiercebiotech.com/biotech/dynacure-calls-it-quits-top-asset-dismay-myotubular-community",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "7/7/2022",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Myotubular and Centronuclear Myopathies",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "N",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Editas Medicines",
    "Candidate": "EDIT-301",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Micro",
    "Headcount": "",
    "MarketCapRange": "50-100M",
    "TotalFunding": "",
    "LastFundraise": "$57,000,000.00",
    "LastFundraiseType": "Cas9 license agreement",
    "Funding type": "Licensing ",
    "FundraiseDate": "10/3/2024",
    "FundingNotes": "Licensing agreement with Vertex/DRI Healthcare Trust ",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 1/2",
    "CurrentStudyStatus": "Active, not recruiting",
    "Current Study": "https://clinicaltrials.gov/study/NCT04853576?intr=edit-301&rank=3",
    "EstimatedStudyCompletion": "2025-08",
    "LastStatusUpdate": "2025-01-29",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "Sickle Cell Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Egetis Therapeutics",
    "Candidate": "Emcitate",
    "CompanyWebsite": "",
    "Company 2": "PledPharma and Rare Thyroid Therapeutic",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "SE",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Micro",
    "Headcount": "",
    "MarketCapRange": "100-250M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 2b",
    "PRV Status": "Phase 3",
    "CurrentStudyStatus": "Recruiting",
    "Current Study": "https://clinicaltrials.gov/study/NCT05579327?cond=MCT8%20Deficiency&rank=4",
    "EstimatedStudyCompletion": "2025-06",
    "LastStatusUpdate": "2025-01-10",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "MCT8 Deficiency",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "Tiratricol",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Eli Lilly",
    "Candidate": "PR001",
    "CompanyWebsite": "",
    "Company 2": "Prevail Therapeutics",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mega",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Big pharma",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "Phase 1/2",
    "CurrentStudyStatus": "Active, not recruiting",
    "Current Study": "https://clinicaltrials.gov/study/NCT04411654?intr=LY3884961&rank=2",
    "EstimatedStudyCompletion": "2028-05",
    "LastStatusUpdate": "2025-02-12",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Neuronopathic Gaucher Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Elpida Therapeutics",
    "Candidate": "MELPIDA",
    "CompanyWebsite": "https://www.elpidatx.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Grant-Supported",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "$4,000,000.00",
    "LastFundraise": "$4,000,000.00",
    "LastFundraiseType": "CIRM Grant",
    "Funding type": "Government grant",
    "FundraiseDate": "2/12/2024",
    "FundingNotes": "Elipida is a parent/advocate-founded biotech. ",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 2",
    "PRV Status": "Phase 3",
    "CurrentStudyStatus": "Not yet recruiting",
    "Current Study": "https://clinicaltrials.gov/study/NCT06692712",
    "EstimatedStudyCompletion": "2032-06-01",
    "LastStatusUpdate": "2024-11-14",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Spastic Paraplegia Type 50",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Encoded Therapeutics",
    "Candidate": "ETX101",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Series D",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "$239,000,000.00",
    "LastFundraise": "$135,000,000.00",
    "LastFundraiseType": "Series D",
    "Funding type": "Venture",
    "FundraiseDate": "7/22/2020",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 1/2",
    "CurrentStudyStatus": "Recruiting",
    "Current Study": "https://clinicaltrials.gov/study/NCT05419492",
    "EstimatedStudyCompletion": "2031-04",
    "LastStatusUpdate": "2025-01-29",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "SCN1A+ Dravet Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Enliven Therapeutics",
    "Candidate": "IMR-687",
    "CompanyWebsite": "https://www.enliventherapeutics.com/",
    "Company 2": "Imara",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "1-5B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 2b",
    "PRV Status": "",
    "CurrentStudyStatus": "Likely terminated",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "B-Thalassemia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "EspeRare Foundation",
    "Candidate": "rimeporide",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "CH",
    "Public/Private": "Non Profit",
    "MarketCapRPD": "",
    "MarketCap": "Advocacy",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1b",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "GEMMABio",
    "Candidate": "PBGM01",
    "CompanyWebsite": "https://www.gemmabiotx.com/",
    "Company 2": "Passage Bio",
    "Company 2 Context": "Licensed from",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Seed",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "$34,000,000.00",
    "LastFundraiseType": "Seed",
    "Funding type": "Venture",
    "FundraiseDate": "8/1/2024",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "2024-08",
    "StatusNote": "Out-licensed from Passage Bio",
    "StatusNoteLink": "https://www.passagebio.com/investors-and-news/press-releases-and-statements/news-details/2024/Passage-Bio-Out-licenses-Three-Pediatric-Gene-Therapy-Programs-to-GEMMA-Biotherapeutics-and-Enters-New-Research-Collaboration/default.aspx",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "GM 1 Gangliosidosis",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "GEMMABio",
    "Candidate": "PBKR03",
    "CompanyWebsite": "https://www.gemmabiotx.com/",
    "Company 2": "Passage Bio",
    "Company 2 Context": "Licensed from",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Seed",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "$34,000,000.00",
    "LastFundraiseType": "Seed",
    "Funding type": "Venture",
    "FundraiseDate": "8/1/2024",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "2024-08",
    "StatusNote": "Out-licensed from Passage Bio",
    "StatusNoteLink": "https://www.passagebio.com/investors-and-news/press-releases-and-statements/news-details/2024/Passage-Bio-Out-licenses-Three-Pediatric-Gene-Therapy-Programs-to-GEMMA-Biotherapeutics-and-Enters-New-Research-Collaboration/default.aspx",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Krabbe Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Genentech",
    "Candidate": "EVRYSDI",
    "CompanyWebsite": "",
    "Company 2": "PTC Therapeutics",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mega",
    "Headcount": "",
    "MarketCapRange": "250-500B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2020",
    "PRV Month": "8",
    "Date": "25",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Spinal muscular atrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "risdiplam",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "RNA splicing modifier",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "NA",
    "Purchase Date": "Na",
    "Purchase Year": "NA",
    "Acquisition": "N",
    "Acquirer": "NA",
    "Acquisition Price": "NA",
    "Acq month": "NA",
    "Acq date": "Na",
    "Acq year": "NA",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "6/1/14",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "9/1/18",
    "BLA submission": "10/1/19"
  },
  {
    "Company": "Genfit S.A.",
    "Candidate": "VS-01",
    "CompanyWebsite": "https://www.genfit.com/",
    "Company 2": "Versantis",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "FR",
    "Public/Private": "Public",
    "MarketCapRPD": "f",
    "MarketCap": "Micro",
    "Headcount": "",
    "MarketCapRange": "100-250M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Urea Cycle Disorders",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "GlycoMimetics",
    "Candidate": "rivipansel",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "10-25M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Pivotal stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 3",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "Sickle Cell Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "GW Pharmaceuticals",
    "Candidate": "EPIDIOLEX",
    "CompanyWebsite": "https://www.jazzpharma.com/",
    "Company 2": "Jazz Pharmaceuticals",
    "Company 2 Context": "Parent company",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "UK",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2018",
    "PRV Month": "7",
    "Date": "19",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Lennox-Gastaut Syndrome",
    "Approved Drug": "Y",
    "FDA-Approved Therapy Prior to 2012": "Felbatol; Onfi; Lamictal; Topamax; Banzel",
    "Active Ingredient": "cannabidiol",
    "Class1": "Organic Chemicals",
    "Class2": "",
    "Class3": "",
    "MOA": "cannabidiol",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Biohaven",
    "Sale Price (USD Millions)": "105",
    "Purchase Month": "3",
    "Purchase Date": "19",
    "Purchase Year": "2019",
    "Acquisition": "N",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "7/1/13",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "11/1/16",
    "BLA submission": "5/1/18"
  },
  {
    "Company": "Q32 Bio",
    "Candidate": "HMI-202",
    "CompanyWebsite": "",
    "Company 2": "Homology Medicines",
    "Company 2 Context": "Merger",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Acquired",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "10-25M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Metachromatic Leukodystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Hubble Therapeutics",
    "Candidate": "HUB-101",
    "CompanyWebsite": "https://hubbletx.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Series A",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "$17,100,000.00",
    "LastFundraise": "$7,300,000.00",
    "LastFundraiseType": "Series A",
    "Funding type": "Venture",
    "FundraiseDate": "3/26/2025",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 1",
    "CurrentStudyStatus": "Initiating",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "",
    "Indication": "Leber Congenital Amaurosis 16",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Immusoft",
    "Candidate": "iduronicrin genleukocel-T (ISP-001)",
    "CompanyWebsite": "https://www.immusoft.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Series C",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "$49,300,000.00",
    "LastFundraise": "$8,000,000.00",
    "LastFundraiseType": "Grant ",
    "Funding type": "Government grant",
    "FundraiseDate": "1/27/2023",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Mucopolysaccharidosis I",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Innova Therapeutics",
    "Candidate": "IVT-8086",
    "CompanyWebsite": "https://www.innovatherapeutics.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Series A",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "$18,000,000.00",
    "LastFundraiseType": "Pre-A",
    "Funding type": "Venture",
    "FundraiseDate": "9/1/2023",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Osteosarcoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Inozyme Pharma",
    "Candidate": "INZ-701",
    "CompanyWebsite": "https://www.inozyme.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "ENPP1 Deficiency",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Ionis Pharmaceuticals",
    "Candidate": "ION373 (Zilganersen)",
    "CompanyWebsite": "https://ionis.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Alexander Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Ipsen Bio",
    "Candidate": "SOHONOS",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "FR",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2023",
    "PRV Month": "9",
    "Date": "7",
    "TherapeuticArea1": "Orthopedics",
    "TherapeuticArea2": "",
    "Indication": "Fibrodysplasia Ossificans Progressiva",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "palovarotene",
    "Class1": "Hypoglycemic Agents",
    "Class2": "",
    "Class3": "",
    "MOA": "Retinoic acid receptor gamma agonist",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Undisclosed",
    "Sale Price (USD Millions)": "158",
    "Purchase Month": "8",
    "Purchase Date": "27",
    "Purchase Year": "2024",
    "Acquisition": "N",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Italfarmaco S.p.A.",
    "Candidate": "DUVYZAT",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "IT",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Mid",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2024",
    "PRV Month": "3",
    "Date": "21",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "givinostat",
    "Class1": "Enzyme inhibitor",
    "Class2": "",
    "Class3": "",
    "MOA": "Histone deacetylase inhibitor",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "N",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "J&J",
    "Candidate": "nipocalimab",
    "CompanyWebsite": "",
    "Company 2": "Momenta Pharmaceuticals",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mega",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Big pharma",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "Hemolytic Disease of the Fetus and Newborn",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Kazia Therapeutics",
    "Candidate": "paxalisib/DIPG",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "AU",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "0-10M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Diffuse Intrinsic Pontine Glioma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Khondrion",
    "Candidate": "sonlicromanol",
    "CompanyWebsite": "https://www.khondrion.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "NL",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "$3,000,000.00",
    "LastFundraise": "Undisclosed",
    "LastFundraiseType": "Undisclosed",
    "Funding type": "",
    "FundraiseDate": "11/21/2024",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "8",
    "RPDD Date": "28",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 2b",
    "PRV Status": "Phase 2",
    "CurrentStudyStatus": "Suspended",
    "Current Study": "https://clinicaltrials.gov/study/NCT04846036?intr=Sonlicromanol&rank=2",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "2025-01-08",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "MELAS Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Laboratoires ThÃ©a",
    "Candidate": "Ultervursen (QR-421a)",
    "CompanyWebsite": "https://www.laboratoires-thea.com/en",
    "Company 2": "ProQR Therapeutics NV",
    "Company 2 Context": "Sold asset to",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "FR",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Series A",
    "Headcount": "",
    "MarketCapRange": "50-100M",
    "TotalFunding": "",
    "LastFundraise": "$10,500,000.00",
    "LastFundraiseType": "Series A",
    "Funding type": "Venture",
    "FundraiseDate": "10/12/2023",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Pivotal",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "Phase 2b",
    "CurrentStudyStatus": "Recruiting",
    "Current Study": "https://clinicaltrials.gov/study/NCT06627179?cond=Retinitis%20Pigmentosa&rank=8",
    "EstimatedStudyCompletion": "2027-12",
    "LastStatusUpdate": "3/7/2025",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "",
    "Indication": "Retinitis Pigmentosa",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "antisense oligonucleotide",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "Y",
    "AssetAcquirer": "8M eur",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Mereo BioPharma",
    "Candidate": "setrusumab",
    "CompanyWebsite": "",
    "Company 2": "Ultragenyx",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "UK",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "250-500M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 2b",
    "PRV Status": "Phase 3",
    "CurrentStudyStatus": "Active, not recruiting",
    "Current Study": "https://clinicaltrials.gov/study/NCT05768854?rank=1",
    "EstimatedStudyCompletion": "2026-06",
    "LastStatusUpdate": "2025-02-20",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Rheumatology",
    "TherapeuticArea2": "",
    "Indication": "Osteogenesis Imperfecta",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Minoryx Therapeutics",
    "Candidate": "leriglitazone",
    "CompanyWebsite": "https://www.minoryx.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "ES",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Micro",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "$125,000,000.00",
    "LastFundraise": "$55,000,000.00",
    "LastFundraiseType": "C/debt",
    "Funding type": "",
    "FundraiseDate": "5/31/2022",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Pivotal",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 2/3",
    "PRV Status": "Phase 3",
    "CurrentStudyStatus": "Active",
    "Current Study": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000654-59/ES",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Adrenoleukodystrophy (X-ALD)",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Moleculin Biotech",
    "Candidate": "WP1066/ATRT",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "10-25M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Atypical Teratoid Rhabdoid Tumor",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Moleculin Biotech",
    "Candidate": "WP1066/DIPG",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "10-25M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Diffuse Intrinsic Pontine Glioma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Moleculin Biotech",
    "Candidate": "WP1066/MB",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "10-25M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Medulloblastoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Mustang Bio",
    "Candidate": "MB-107",
    "CompanyWebsite": "",
    "Company 2": "Fortress Biotech",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "0-10M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Immunology",
    "TherapeuticArea2": "",
    "Indication": "X-linked Severe Combined Immunodeficiency",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Mustang Bio",
    "Candidate": "MB-207",
    "CompanyWebsite": "",
    "Company 2": "Fortress Biotech",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "0-10M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Immunology",
    "TherapeuticArea2": "",
    "Indication": "X-linked Severe Combined Immunodeficiency",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "National Cancer Institute",
    "Candidate": "CD22 CAR T-cell therapy",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Non Profit",
    "MarketCapRPD": "",
    "MarketCap": "Government",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "B-cell Acute Lymphoblastic Leukemia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Neurocrine Biosciences",
    "Candidate": "Crenessity",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "10-50B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2024",
    "PRV Month": "12",
    "Date": "13",
    "TherapeuticArea1": "Endocrinology",
    "TherapeuticArea2": "",
    "Indication": "Congenital Adrenal Hyperplasia",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "crinecerfont",
    "Class1": "Pharmacotherapies",
    "Class2": "",
    "Class3": "",
    "MOA": "CRF receptor type 1 and 2 antagonist",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "NA",
    "Purchase Date": "Na",
    "Purchase Year": "NA",
    "Acquisition": "N",
    "Acquirer": "NA",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Neurocrine Biosciences",
    "Candidate": "NBI-921352",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "10-50B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "SCN8A developmental and epileptic encephalopathy (SCN8A-DEE)",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Novadip Biosciences",
    "Candidate": "NVD-003",
    "CompanyWebsite": "www.novadip.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "BE",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Series B",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "$105,000,000.00",
    "LastFundraise": "$26,000,000.00",
    "LastFundraiseType": "Series B",
    "Funding type": "Venture",
    "FundraiseDate": "11/3/2022",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Orthopedics",
    "TherapeuticArea2": "",
    "Indication": "Congenital Pseudarthrosis of the Tibia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Novartis",
    "Candidate": "ZOLGENSMA",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "CH",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mega",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2019",
    "PRV Month": "6",
    "Date": "24",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Spinal muscular atrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "onasemnogene abeparvovec-xioi",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "Gene correction",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "NA",
    "Purchase Date": "NA",
    "Purchase Year": "NA",
    "Acquisition": "N",
    "Acquirer": "NA",
    "Acquisition Price": "NA",
    "Acq month": "NA",
    "Acq date": "NA",
    "Acq year": "NA",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "4/1/15",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "8/1/18",
    "BLA submission": "2/1/19"
  },
  {
    "Company": "Novartis",
    "Candidate": "iptacopan (LNP023)",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "CH",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mega",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Big pharma",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 3",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Nephrology",
    "TherapeuticArea2": "",
    "Indication": "C3 glomerulopathy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Novo Nordisk",
    "Candidate": "FT-4202",
    "CompanyWebsite": "",
    "Company 2": "Forma Therapeutics",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "DK",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mega",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Big pharma",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "Sickle Cell Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Novo Nordisk",
    "Candidate": "nedosiran",
    "CompanyWebsite": "",
    "Company 2": "Dicerna Pharmaceuticals",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "DK",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mega",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Big pharma",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Nephrology",
    "TherapeuticArea2": "",
    "Indication": "Primary Hyperoxaluria",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Oblato",
    "Candidate": "OKN-007",
    "CompanyWebsite": "oblatoinc.com/",
    "Company 2": "GtreeBNT",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "KR",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Series A",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "$12,500,000.00",
    "LastFundraiseType": "A",
    "Funding type": "",
    "FundraiseDate": "2/5/2023",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "9",
    "RPDD Date": "2",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 2",
    "PRV Status": "Expanded Access",
    "CurrentStudyStatus": "No longer available",
    "Current Study": "https://www.clinicaltrials.gov/study/NCT05518838?intr=OKN-007&rank=2",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "2024-11-06",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Diffuse Intrinsic Pontine Glioma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Oncoheroes Biosciences",
    "Candidate": "volasertib",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Seed",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "$1,030,000.00",
    "LastFundraiseType": "Seed",
    "Funding type": "Crowdfunding",
    "FundraiseDate": "5/29/2024",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Rhabdomyosarcoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Oncotelic",
    "Candidate": "OXi4503",
    "CompanyWebsite": "https://www.oncotelic.com/",
    "Company 2": "Mateon Therapeutics",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "10-25M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "5",
    "RPDD Date": "4",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1b",
    "PRV Status": "Phase 1",
    "CurrentStudyStatus": "Unknown",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Acute Myeloid Leukemia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "combretastatin A1-diphosphate; CA1P)",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Oncternal Therapeutics",
    "Candidate": "ONCT-216 (TK216)",
    "CompanyWebsite": "https://www.oncternal.com/",
    "Company 2": "Shanghai Pharmaceuticals Holding Co",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "0-10M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "As of 3/5/2025, intends to delist from NASDAQ",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1",
    "PRV Status": "Phase 1",
    "CurrentStudyStatus": "Licensed to Shanghai Pharma",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Ewing's Sarcoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Orchard Therapeutics",
    "Candidate": "OTL-203",
    "CompanyWebsite": "",
    "Company 2": "Kyowa Kirin",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "UK",
    "Public/Private": "Acquired",
    "MarketCapRPD": "",
    "MarketCap": "Mid",
    "Headcount": "",
    "MarketCapRange": "5-10B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 2",
    "PRV Status": "Phase 3",
    "CurrentStudyStatus": "Active, no longer recruiting",
    "Current Study": "https://clinicaltrials.gov/study/NCT06149403?intr=OTL-203&rank=1",
    "EstimatedStudyCompletion": "2025-03-24",
    "LastStatusUpdate": "2025-03-24",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Mucopolysaccharidosis I",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "Y",
    "Acquirer": "Kyowa Kirin",
    "Acquisition Price": "$477,600,000.00",
    "Acq month": "10",
    "Acq date": "5",
    "Acq year": "2023",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Ovid Therapeutics",
    "Candidate": "OV101",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "10-25M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Pivotal stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 3",
    "PRV Status": "Phase 3",
    "CurrentStudyStatus": "Terminated",
    "Current Study": "https://clinicaltrials.gov/study/NCT03882918?intr=Gaboxadol&rank=44",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "2022-01-20",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Angelman Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "OxThera",
    "Candidate": "Oxabact OC5",
    "CompanyWebsite": "https://oxthera.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "SE",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Series D",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "$34,000,000.00",
    "LastFundraiseType": "Series D",
    "Funding type": "Venture",
    "FundraiseDate": "11/29/2016",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Pivotal stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 3",
    "PRV Status": "Phase 3",
    "CurrentStudyStatus": "Terminated",
    "Current Study": "https://clinicaltrials.gov/study/NCT03938272?intr=Oxabact%20OC5&rank=1",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "2021-11-11",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Nephrology",
    "TherapeuticArea2": "",
    "Indication": "Primary Hyperoxaluria",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Parion Sciences",
    "Candidate": "P-1037 Inhalation Solution",
    "CompanyWebsite": "https://www.parion.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Grant-Supported",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "$15,600,000.00",
    "LastFundraiseType": "NIH Grant",
    "Funding type": "Government grant",
    "FundraiseDate": "10/15/2016",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "7",
    "RPDD Date": "29",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 2",
    "PRV Status": "Phase 2",
    "CurrentStudyStatus": "Completed, positive results",
    "Current Study": "https://clinicaltrials.gov/study/NCT02871778?lead=Parion%20Sciences&rank=1",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "September 8, 2023 - Announced publication in The Lancet Respiratory Medicine of positive results of the Phase 2.",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Pulmonology",
    "TherapeuticArea2": "",
    "Indication": "Primary Ciliary Dyskinesia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Passage Bio",
    "Candidate": "PBGM01",
    "CompanyWebsite": "https://www.passagebio.com",
    "Company 2": "GEMMABio ",
    "Company 2 Context": "Licensed to",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "10-25M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 1",
    "CurrentStudyStatus": "Active, not recruiting",
    "Current Study": "https://clinicaltrials.gov/study/NCT04713475?intr=PBGM01&rank=1",
    "EstimatedStudyCompletion": "2029-02",
    "LastStatusUpdate": "2024-05",
    "StatusNote": "Out-licensed to GEMMA Therapeutics",
    "StatusNoteLink": "https://www.passagebio.com/investors-and-news/press-releases-and-statements/news-details/2024/Passage-Bio-Out-licenses-Three-Pediatric-Gene-Therapy-Programs-to-GEMMA-Biotherapeutics-and-Enters-New-Research-Collaboration/default.aspx",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "GM 1 Gangliosidosis",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Passage Bio",
    "Candidate": "PBKR03",
    "CompanyWebsite": "https://www.passagebio.com",
    "Company 2": "GEMMABio ",
    "Company 2 Context": "Licensed to",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "10-25M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "Phase 1/2",
    "CurrentStudyStatus": "Suspended",
    "Current Study": "https://clinicaltrials.gov/study/NCT04771416?intr=PBKR03&rank=1",
    "EstimatedStudyCompletion": "2030-01",
    "LastStatusUpdate": "2024-01-18",
    "StatusNote": "Out-licensed to GEMMA Therapeutics",
    "StatusNoteLink": "https://www.passagebio.com/investors-and-news/press-releases-and-statements/news-details/2024/Passage-Bio-Out-licenses-Three-Pediatric-Gene-Therapy-Programs-to-GEMMA-Biotherapeutics-and-Enters-New-Research-Collaboration/default.aspx",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Krabbe Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Percheron Therapeutics",
    "Candidate": "ATL-1102",
    "CompanyWebsite": "https://percherontx.com/",
    "Company 2": "Antisense Therapeutics",
    "Company 2 Context": "Ex",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "AU",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "0-10M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 2",
    "PRV Status": "Phase 2, missed endpoints",
    "CurrentStudyStatus": "Terminated",
    "Current Study": "https://clinicaltrials.gov/study/NCT05938023",
    "EstimatedStudyCompletion": "2025-01-15",
    "LastStatusUpdate": "2025-01-30",
    "StatusNote": "Missed primary and secondary endpoints. Intends to abandon candidate.",
    "StatusNoteLink": "https://www.ntnews.com.au/business/stockhead/health-check-percheron-closes-the-book-on-failed-childhood-rare-disease-program/news-story/7c09ca976c85bb08d1536f5c85313375",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Pharming Group N.V.",
    "Candidate": "JOENJA",
    "CompanyWebsite": "https://www.pharming.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "NL",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mid",
    "Headcount": "",
    "MarketCapRange": "500M-1B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2023",
    "PRV Month": "3",
    "Date": "24",
    "TherapeuticArea1": "Immunology",
    "TherapeuticArea2": "",
    "Indication": "Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS)",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "leniolisib",
    "Class1": "Enzyme inhibitor",
    "Class2": "",
    "Class3": "",
    "MOA": "PI3K-delta inhibitor",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Novartis",
    "Sale Price (USD Millions)": "21",
    "Purchase Month": "6",
    "Purchase Date": "1",
    "Purchase Year": "2023",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Plakous Therapeutics",
    "Candidate": "Protego-PDâ„¢",
    "CompanyWebsite": "https://www.plakoustherapeutics.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Grant-Supported",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "$3,000,000.00",
    "LastFundraiseType": "NIH Grant",
    "Funding type": "Government grant",
    "FundraiseDate": "7/2/2022",
    "FundingNotes": "As of 7/2024 -- Struggling to raise venture funding of 10M.",
    "FundingNotesLink": "https://www.bizjournals.com/triad/news/2024/07/10/plakous-therapeutics-3m-nih-grant-winston-salem.html",
    "Commercial stage": "Early stage",
    "RPDD Month": "6",
    "RPDD Date": "19",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Preclinical",
    "CurrentStudyStatus": "IND-enabling studies",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Gastroenterology",
    "TherapeuticArea2": "",
    "Indication": "Necrotizing Enterocolitis",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Polaryx Therapeutics",
    "Candidate": "PLX-300/GM2",
    "CompanyWebsite": "https://polaryx.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Seed",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "Undisclosed",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "Majority shareholder is Mstone Healthcare",
    "FundingNotesLink": "",
    "Commercial stage": "Pivotal stage",
    "RPDD Month": "11",
    "RPDD Date": "25",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "GM2 Gangliosidosis",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Polaryx Therapeutics",
    "Candidate": "PLX-300/NP",
    "CompanyWebsite": "https://polaryx.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Seed",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "Undisclosed",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "Majority shareholder is Mstone Healthcare",
    "FundingNotesLink": "",
    "Commercial stage": "Pivotal stage",
    "RPDD Month": "12",
    "RPDD Date": "18",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Niemann Pick Disease A/B",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "PTC Therapeutics",
    "Candidate": "PTC596",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "1-10B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1b",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Diffuse Intrinsic Pontine Glioma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Reata Pharmaceuticals",
    "Candidate": "SKYCLARYS",
    "CompanyWebsite": "",
    "Company 2": "Biogen",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Acquired",
    "MarketCapRPD": "",
    "MarketCap": "Mid",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2023",
    "PRV Month": "3",
    "Date": "16",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Friedreich's ataxia",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "omaveloxolone",
    "Class1": "Peptides",
    "Class2": "",
    "Class3": "",
    "MOA": "Nuclear factor erythroid 2-related factor 2 (Nrf2) activator",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "NA",
    "Purchase Date": "NA",
    "Purchase Year": "NA",
    "Acquisition": "Y",
    "Acquirer": "Biogen",
    "Acquisition Price": "$7,300,000,000.00",
    "Acq month": "9",
    "Acq date": "26",
    "Acq year": "2023",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Regeneron",
    "Candidate": "VEOPOZ",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "50-100B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2023",
    "PRV Month": "9",
    "Date": "7",
    "TherapeuticArea1": "Immunology",
    "TherapeuticArea2": "",
    "Indication": "CD55-deficient protein-losing enteropathy (PLE) (CHAPLE disease)",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "pozelimab-bbfg",
    "Class1": "Immunosuppresant",
    "Class2": "",
    "Class3": "",
    "MOA": "TNF-alpha inhibitor",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "NA",
    "Purchase Date": "Na",
    "Purchase Year": "NA",
    "Acquisition": "N",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "reVision Therapeutics",
    "Candidate": "REV-0100",
    "CompanyWebsite": "https://www.revisiontx.com/",
    "Company 2": "Aequus Pharmaceuticals",
    "Company 2 Context": "Partnership/joint venture",
    "Company 3": "Cornell",
    "Company 3 Context": "Originator",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Seed",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "Undisclosed",
    "LastFundraiseType": "Partnership equity",
    "Funding type": "Partnership equity investment",
    "FundraiseDate": "8/17/2021",
    "FundingNotes": "As part of the option terms, Aequus will make an equity investment in reVision with the option to fully fund the development program in return for the North American commercial rights.",
    "FundingNotesLink": "https://www.revisiontx.com/aequus-and-revision-collaborate-on-stargardt-program",
    "Commercial stage": "Early stage",
    "RPDD Month": "10",
    "RPDD Date": "28",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 1",
    "CurrentStudyStatus": "Initiating",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "",
    "Indication": "Stargardt Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Rezolute",
    "Candidate": "RZ358",
    "CompanyWebsite": "https://www.rezolutebio.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Micro",
    "Headcount": "",
    "MarketCapRange": "100-250M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Pivotal stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 2b",
    "PRV Status": "Phase 3",
    "CurrentStudyStatus": "Recruiting",
    "Current Study": "https://clinicaltrials.gov/study/NCT06208215?intr=RZ358&rank=1",
    "EstimatedStudyCompletion": "2026-09-28",
    "LastStatusUpdate": "2025-03-04",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Endocrinology",
    "TherapeuticArea2": "",
    "Indication": "Congenital Hyperinsulinism",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Rhythm Biosciences",
    "Candidate": "IMCIVREE",
    "CompanyWebsite": "https://rhythmbio.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "10-25M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "7",
    "RPDD Date": "1",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 3",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2020",
    "PRV Month": "12",
    "Date": "17",
    "TherapeuticArea1": "Endocrinology",
    "TherapeuticArea2": "",
    "Indication": "POMC, PCSK1, and LEPR deficiency",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "setmelanotide",
    "Class1": "Analogs & derivatives",
    "Class2": "",
    "Class3": "",
    "MOA": "Melanocortin-4 receptor agonist",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Alexion",
    "Sale Price (USD Millions)": "100",
    "Purchase Month": "1",
    "Purchase Date": "11",
    "Purchase Year": "2021",
    "Acquisition": "N",
    "Acquirer": "NA",
    "Acquisition Price": "NA",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Rosa Bacchetta",
    "Candidate": "CD4+ T cells Gene Therapy",
    "CompanyWebsite": "",
    "Company 2": "Stanford",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Non Profit",
    "MarketCapRPD": "",
    "MarketCap": "Academic",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Immunology",
    "TherapeuticArea2": "",
    "Indication": "IPEX syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "RyCarma Therapeutics",
    "Candidate": "ARM210",
    "CompanyWebsite": "https://rycarma.com/",
    "Company 2": "ARMGO Pharma",
    "Company 2 Context": "Rebranded company",
    "Company 3": "https://rycarma.com/",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "11-50",
    "MarketCap": "Series B",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "$35,000,000.00",
    "LastFundraiseType": "Series B",
    "Funding type": "Venture",
    "FundraiseDate": "12/20/2021",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1",
    "PRV Status": "Phase 2",
    "CurrentStudyStatus": "Terminated",
    "Current Study": "https://clinicaltrials.gov/study/NCT05122975?cond=Catecholaminergic%20Polymorphic%20Ventricular%20Tachycardia&rank=7",
    "EstimatedStudyCompletion": "2024-04-01",
    "LastStatusUpdate": "2024-09-10",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Cardiology",
    "TherapeuticArea2": "",
    "Indication": "Catecholaminergic Polymorphic Ventricular Tachycardia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Sanofi",
    "Candidate": "Xenpozyme",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "FR",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mega",
    "Headcount": "",
    "MarketCapRange": "100-200B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2023",
    "PRV Month": "12",
    "Date": "5",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Acid sphingomyelinase deficiency (ASMD)",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "olipudase alfa-rpcp",
    "Class1": "Enzyme Replacement",
    "Class2": "",
    "Class3": "",
    "MOA": "Acid sphingomyelinase enzyme replacement",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "N",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Sarepta Therapeutics",
    "Candidate": "ELEVIDYS",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mid",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2023",
    "PRV Month": "7",
    "Date": "17",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "delandistrogene moxeparvovec-rokl",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "AAV",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Undisclosed",
    "Sale Price (USD Millions)": "102",
    "Purchase Month": "7",
    "Purchase Date": "5",
    "Purchase Year": "2023",
    "Acquisition": "Y",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Scholar Rock",
    "Candidate": "SRK-015",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "1-10B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "8",
    "RPDD Date": "13",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Spinal Muscular Atrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Seelos Therapeutics",
    "Candidate": "SLS-005",
    "CompanyWebsite": "https://seelostherapeutics.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Bankrupt",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "Delisted from NASDAQ",
    "FundingNotesLink": "https://www.fiercebiotech.com/biotech/after-als-trial-misses-mark-seelos-has-filed-bankruptcy#:~:text=After%20Seelos%20Therapeutics'%20amyotrophic%20lateral,of%2010:30%20a.m.%20ET.",
    "Commercial stage": "Pivotal stage",
    "RPDD Month": "5",
    "RPDD Date": "15",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 2b/3",
    "PRV Status": "",
    "CurrentStudyStatus": "Terminated",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Sanfilippo Syndrome (A & B)",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Senhwa Biosciences",
    "Candidate": "Silmitasertib/SH",
    "CompanyWebsite": "https://www.senhwabio.com/en",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "TW",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "50-100M ",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "Phase 1/2",
    "CurrentStudyStatus": "Recruiting",
    "Current Study": "https://clinicaltrials.gov/study/NCT03904862?intr=Silmitasertib&rank=6",
    "EstimatedStudyCompletion": "2030-02-21",
    "LastStatusUpdate": "2025-01-29",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Recurrent Sonic Hedgehog Medulloblastoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Shanghai Pharmaceuticals Holding Co",
    "Candidate": "TK216 (ONCT-216)",
    "CompanyWebsite": "https://www.sphbio.com/view/home/home.html",
    "Company 2": "Oncternal Therapeutics",
    "Company 2 Context": "Licensed from ",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "CN",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "1-10B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1",
    "PRV Status": "Phase 2",
    "CurrentStudyStatus": "Recruiting",
    "Current Study": "https://clinicaltrials.gov/study/NCT05046314?intr=TK216&rank=1",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "2024-12-19",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Ewing's Sarcoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Silence Therapeutics",
    "Candidate": "SLN124",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "UK",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Micro",
    "Headcount": "",
    "MarketCapRange": "100-250M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1b",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "Beta Thalassemia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "SIO Gene Therapies",
    "Candidate": "AXO-AAV-GM1",
    "CompanyWebsite": "",
    "Company 2": "Axovant Gene Therapies",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "25-50M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "10",
    "RPDD Date": "12",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "Liquidated",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "GM1 Gangliosidosis",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "SIO Gene Therapies",
    "Candidate": "AXO-AAV-GM2",
    "CompanyWebsite": "",
    "Company 2": "Axovant Gene Therapies",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "25-50M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "10",
    "RPDD Date": "12",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "Liquidated",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "GM2 Gangliosidosis",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Spark Therapeutics",
    "Candidate": "LUXTURNA",
    "CompanyWebsite": "sparktx.com",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Acquired",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2018",
    "PRV Month": "1",
    "Date": "2",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "",
    "Indication": "Biallelic RPE65 mutation-associated retinal dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "voretigene neparvovec",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Jazz",
    "Sale Price (USD Millions)": "110",
    "Purchase Month": "Apr",
    "Purchase Date": "30",
    "Purchase Year": "2018",
    "Acquisition": "Y",
    "Acquirer": "Roche",
    "Acquisition Price": "$4,300,000,000.00",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Spirovant",
    "Candidate": "SPIRO-2101",
    "CompanyWebsite": "https://spirovant.com/",
    "Company 2": "Ruagen Bio",
    "Company 2 Context": "Parent company of",
    "Company 3": "Sumitomo",
    "Company 3 Context": "",
    "COUNTRY": "JP",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 1/2",
    "CurrentStudyStatus": "Recruiting",
    "Current Study": "https://www.clinicaltrials.gov/study/NCT06526923?cond=Cystic%25",
    "EstimatedStudyCompletion": "2024-11-21",
    "LastStatusUpdate": "2026-12-31",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Pulmonology",
    "TherapeuticArea2": "",
    "Indication": "Cystic Fibrosis",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Spyre Therapeutics",
    "Candidate": "AGLE-102",
    "CompanyWebsite": "",
    "Company 2": "Aeglea Therapeutics",
    "Company 2 Context": "Prev name",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "   ",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "1-5B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Dermatology",
    "TherapeuticArea2": "",
    "Indication": "Dystrophic Epidermolysis Bullosa",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Spyre Therapeutics",
    "Candidate": "Pegtarviliase (ACN00177)",
    "CompanyWebsite": "",
    "Company 2": "Aeglea Therapeutics",
    "Company 2 Context": "Prev name",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "1-5B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Homocystinuria",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Stealth BioTherapeutics",
    "Candidate": "elamipretide",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "10-25M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Cardiology",
    "TherapeuticArea2": "",
    "Indication": "Barth Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Taysha Gene Therapies",
    "Candidate": "TSHA-101",
    "CompanyWebsite": "https://tayshagtx.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "250-500M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "GM2 Gangliosidosis",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Taysha Gene Therapies",
    "Candidate": "TSHA-102",
    "CompanyWebsite": "https://tayshagtx.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "250-500M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Rett Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Taysha Gene Therapies",
    "Candidate": "TSHA-104",
    "CompanyWebsite": "https://tayshagtx.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "250-500M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "SURF1-Associated Leigh Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Tellus Therapeutics",
    "Candidate": "TT-20",
    "CompanyWebsite": "https://www.tellustherapeutics.com/contact/#:~:text=Location,jasonkralic@tellustherapeutics.com).",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Series A",
    "Headcount": "10-50",
    "MarketCapRange": "",
    "TotalFunding": "$53,500,000.00",
    "LastFundraise": "$16,000,000.00",
    "LastFundraiseType": "Series A",
    "Funding type": "Venture",
    "FundraiseDate": "2/21/2023",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "10",
    "RPDD Date": "21",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Preclinical",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Diffuse White Matter Injury",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Tharimmune",
    "Candidate": "HSB-888",
    "CompanyWebsite": "https://tharimmune.com/",
    "Company 2": "Hillstream BioPharma",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "1-5M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Osteosarcoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Theranexus",
    "Candidate": "BBDF-101",
    "CompanyWebsite": "https://www.theranexus.com/en/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "FR",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "1-5M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Pivotal",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 1/2",
    "CurrentStudyStatus": "Positive results",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Batten Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Translate Bio",
    "Candidate": "MRT5005",
    "CompanyWebsite": "",
    "Company 2": "Sanofi",
    "Company 2 Context": "Acquisition",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "FR",
    "Public/Private": "Acquired",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "`",
    "RPDD Date": "26",
    "RPDD Year": "2020",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "Terminated",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Pulmonology",
    "TherapeuticArea2": "",
    "Indication": "Cystic Fibrosis",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "Y",
    "Acquirer": "Sanofi",
    "Acquisition Price": "$3,200,000,000.00",
    "Acq month": "8",
    "Acq date": "3",
    "Acq year": "2021",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Ultragenyx",
    "Candidate": "Mepsevii",
    "CompanyWebsite": "https://www.ultragenyx.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "1-10B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2017",
    "PRV Month": "11",
    "Date": "15",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Mucopolysaccharidosis Type VII (Sly Syndrome)",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "vestronidase alfa-vjbk",
    "Class1": "Enzyme Replacement",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Novartis",
    "Sale Price (USD Millions)": "130",
    "Purchase Month": "12",
    "Purchase Date": "18",
    "Purchase Year": "2017",
    "Acquisition": "N",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Ultragenyx",
    "Candidate": "CRYSVITA",
    "CompanyWebsite": "https://www.ultragenyx.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "1-10B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2018",
    "PRV Month": "8",
    "Date": "15",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "X-linked hypophosphatemia(HPP)",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "burosamab-twza",
    "Class1": "Immunotherapy",
    "Class2": "",
    "Class3": "",
    "MOA": "FGF23-blocking monoclonal antibody",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "NA",
    "Purchase Date": "NA",
    "Purchase Year": "NA",
    "Acquisition": "N",
    "Acquirer": "NA",
    "Acquisition Price": "NA",
    "Acq month": "NA",
    "Acq date": "NA",
    "Acq year": "NA",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "United Therapeutics",
    "Candidate": "UNITUXIN",
    "CompanyWebsite": "https://www.unither.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mid",
    "Headcount": "",
    "MarketCapRange": "10-50B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2015",
    "PRV Month": "4",
    "Date": "7",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "neuroblastoma",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "dinutuximab",
    "Class1": "Immunotherapy",
    "Class2": "",
    "Class3": "",
    "MOA": "GD2-binding monoclonal antibody",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "AbbVie",
    "Sale Price (USD Millions)": "350",
    "Purchase Month": "11",
    "Purchase Date": "6",
    "Purchase Year": "2015",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "AbbVie buys last available priority voucher for $350 million",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "1/1/11",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "12/1/14",
    "BLA submission": "7/1/14"
  },
  {
    "Company": "Y-mAbs",
    "Candidate": "DANYELZA",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2020",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2020",
    "PRV Month": "12",
    "Date": "7",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "neuroblastoma",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "Immunotherapy",
    "Class2": "",
    "Class3": "",
    "MOA": "Monoclonal antibody (anti-GD2)",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "United",
    "Sale Price (USD Millions)": "105",
    "Purchase Month": "12",
    "Purchase Date": "28",
    "Purchase Year": "2020",
    "Acquisition": "N",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "BioMarin",
    "Candidate": "VIMIZIM",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mid",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2021",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2014",
    "PRV Month": "2",
    "Date": "12",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Morquio A syndrome",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "Elosulfase alfa",
    "Class1": "Enzyme Replacement",
    "Class2": "",
    "Class3": "",
    "MOA": "recombinant chimeric monoclonal antibody to GD2",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Undisclosed",
    "Sale Price (USD Millions)": "68",
    "Purchase Month": "7",
    "Purchase Date": "30",
    "Purchase Year": "2014",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "$68,000,000.00",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "7/1/09",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "9/1/12",
    "BLA submission": "12/1/12"
  },
  {
    "Company": "Eli Lilly",
    "Candidate": "AK-OTOF",
    "CompanyWebsite": "",
    "Company 2": "Akouos",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mega",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Big pharma",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Otolaryngology",
    "TherapeuticArea2": "",
    "Indication": "Otoferlin Gene-mediated Hearing Loss",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Enalare Therapeutics",
    "Candidate": "ENA001",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neonatology",
    "TherapeuticArea2": "",
    "Indication": "Apnea of Prematurity",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Enzyvant",
    "Candidate": "RETHYMIC",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Acquired",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2021",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2021",
    "PRV Month": "10",
    "Date": "27",
    "TherapeuticArea1": "Immunology",
    "TherapeuticArea2": "",
    "Indication": "Congenital athymia",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "allogeneic processed thymus tissue-agdc",
    "Class1": "Biologic",
    "Class2": "",
    "Class3": "",
    "MOA": "Allogeneic thymus tissue therapy",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "NA",
    "Purchase Date": "Na",
    "Purchase Year": "NA",
    "Acquisition": "Y",
    "Acquirer": "Sumitomo",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "5/1/15",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "7/1/18",
    "BLA submission": "8/1/20"
  },
  {
    "Company": "Eureka Therapeutics",
    "Candidate": "ET140203",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Hepatoblastoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "FibroGen",
    "Candidate": "Pamrevlumab",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "4",
    "RPDD Date": "15",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 3",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "N",
    "Active Ingredient": "Pamrevlumab",
    "Class1": "Anti-CTGF antibody",
    "Class2": "Antineoplastics",
    "Class3": "",
    "MOA": "Connective tissue growth factor inhibitors",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "NA",
    "Purchase Date": "Na",
    "Purchase Year": "NA",
    "Acquisition": "N",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Forge Biologics",
    "Candidate": "FBX-101",
    "CompanyWebsite": "",
    "Company 2": "Ajinomoto Co. Inc.",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Acquired",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Krabbe Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "Y",
    "Acquirer": "Ajinomoto Co. Inc.",
    "Acquisition Price": "$620,000,000.00",
    "Acq month": "11",
    "Acq date": "13",
    "Acq year": "2023",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Grace Science",
    "Candidate": "GS-100",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "NGLY1 Deficiency",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Jasper Therapeutics",
    "Candidate": "briquilimab (JSP191)",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Micro",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Immunology",
    "TherapeuticArea2": "",
    "Indication": "Severe Combined Immunodeficiency",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Krystal Biotech",
    "Candidate": "HG302",
    "CompanyWebsite": "https://www.krystalbio.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "1-10B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Leadiant Bioscience",
    "Candidate": "HG204",
    "CompanyWebsite": "https://leadiant.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "8",
    "RPDD Date": "",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "Genetic",
    "Indication": "MECP2 duplication syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "LEXEO Therapeutics",
    "Candidate": "LX2006-02",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Micro",
    "Headcount": "",
    "MarketCapRange": "100-250M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "6",
    "RPDD Date": "30",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Observational",
    "CurrentStudyStatus": "Not yet recruiting",
    "Current Study": "https://clinicaltrials.gov/study/NCT06865482?lead=Lexeo%20Therapeutics&aggFilters=ages:child&rank=1",
    "EstimatedStudyCompletion": "2027-04",
    "LastStatusUpdate": "2025-03-04",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Friedreich Ataxia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Longeveron",
    "Candidate": "Lomecel-B",
    "CompanyWebsite": "https://longeveron.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "10-25M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "11",
    "RPDD Date": "27",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 2",
    "PRV Status": "Phase 2",
    "CurrentStudyStatus": "Recruiting",
    "Current Study": "https://clinicaltrials.gov/study/NCT04925024",
    "EstimatedStudyCompletion": "2025-08-31",
    "LastStatusUpdate": "2025-02-11",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Cardiology",
    "TherapeuticArea2": "",
    "Indication": "Hypoplastic Left Heart Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "M6P Therapeutics",
    "Candidate": "M002",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "Undisclosed",
    "LastFundraiseType": "Undisclosed",
    "Funding type": "",
    "FundraiseDate": "9/1/2022",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "1",
    "RPDD Date": "28",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Pre-IND",
    "CurrentStudyStatus": "Not yet scheduled",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Mucolipidosis III",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "M6P Therapeutics",
    "Candidate": "M011",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "Undisclosed",
    "LastFundraiseType": "Undisclosed",
    "Funding type": "",
    "FundraiseDate": "9/2/2022",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "1",
    "RPDD Date": "28",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Pre-IND",
    "CurrentStudyStatus": "Not yet scheduled",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Gaucher Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "M6P Therapeutics",
    "Candidate": "M012",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "Undisclosed",
    "LastFundraiseType": "Undisclosed",
    "Funding type": "",
    "FundraiseDate": "9/3/2022",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "1",
    "RPDD Date": "28",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Pre-IND",
    "CurrentStudyStatus": "Not yet scheduled",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Gaucher Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "M6P Therapeutics",
    "Candidate": "M021",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "Undisclosed",
    "LastFundraiseType": "Undisclosed",
    "Funding type": "",
    "FundraiseDate": "9/4/2022",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "1",
    "RPDD Date": "28",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Pre-IND",
    "CurrentStudyStatus": "Not yet scheduled",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Pompe Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "M6P Therapeutics",
    "Candidate": "M043",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "Undisclosed",
    "LastFundraiseType": "Undisclosed",
    "Funding type": "",
    "FundraiseDate": "9/5/2022",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "1",
    "RPDD Date": "28",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Pre-IND",
    "CurrentStudyStatus": "Not yet scheduled",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Sanfilippo Syndrome B",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "M6P Therapeutics",
    "Candidate": "M052",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "Undisclosed",
    "LastFundraiseType": "Undisclosed",
    "Funding type": "",
    "FundraiseDate": "9/6/2022",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "1",
    "RPDD Date": "28",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Pre-IND",
    "CurrentStudyStatus": "Not yet scheduled",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Fabry Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Marathon Pharmaceuticals",
    "Candidate": "HG004",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Acquired",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "8",
    "RPDD Date": "",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "Genetic",
    "Indication": "RPE65 mutations inherited retinal disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Marinus Pharmaceuticals",
    "Candidate": "ZTALMY",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Acquired",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2021",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2022",
    "PRV Month": "9",
    "Date": "7",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "cyclin-dependent kinase-like 5 (CDKL5)",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "ganaxolone",
    "Class1": "Enzyme inhibitor",
    "Class2": "",
    "Class3": "",
    "MOA": "GABA receptor modulator",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Novo Nordisk",
    "Sale Price (USD Millions)": "110",
    "Purchase Month": "7",
    "Purchase Date": "14",
    "Purchase Year": "2022",
    "Acquisition": "Y",
    "Acquirer": "Immedica Pharma",
    "Acquisition Price": "$151,000,000.00",
    "Acq month": "12",
    "Acq date": "30",
    "Acq year": "2024",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Moleculin Biotech",
    "Candidate": "WP1066/EP",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "10-25M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Ependymoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Novo Nordisk",
    "Candidate": "INV-101",
    "CompanyWebsite": "",
    "Company 2": "Inversago Pharma",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "DK",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mega",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Big pharma",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Endocrinology",
    "TherapeuticArea2": "",
    "Indication": "Prader-Willi Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Orchard Therapeutics",
    "Candidate": "LENMELDY",
    "CompanyWebsite": "",
    "Company 2": "Kyowa Kirin",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "UK",
    "Public/Private": "Acquired",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2021",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2024",
    "PRV Month": "3",
    "Date": "20",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Metachromatic leukodystrophy(MLD)",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "atidarsagene autotemcel",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "N",
    "Purchaser": "NA",
    "Sale Price (USD Millions)": "NA",
    "Purchase Month": "NA",
    "Purchase Date": "Na",
    "Purchase Year": "NA",
    "Acquisition": "Y",
    "Acquirer": "Kyowa Kirin",
    "Acquisition Price": "$477,600,000.00",
    "Acq month": "10",
    "Acq date": "5",
    "Acq year": "2023",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Orchard Therapeutics",
    "Candidate": "OR-449",
    "CompanyWebsite": "",
    "Company 2": "Kyowa Kirin",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "UK",
    "Public/Private": "Acquired",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "1",
    "RPDD Date": "18",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Adrenocortical Carcinoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "Y",
    "Acquirer": "Kyowa Kirin",
    "Acquisition Price": "$477,600,000.00",
    "Acq month": "10",
    "Acq date": "5",
    "Acq year": "2023",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "OS Therapies",
    "Candidate": "OST-HER2",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 2b",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Osteosarcoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Polaryx Therapeutics",
    "Candidate": "PLX-300",
    "CompanyWebsite": "https://polaryx.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Seed",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "Undisclosed",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "Majority shareholder is Mstone Healthcare",
    "FundingNotesLink": "",
    "Commercial stage": "Pivotal stage",
    "RPDD Month": "2",
    "RPDD Date": "10",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Krabbe Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Polaryx Therapeutics",
    "Candidate": "PLX-200",
    "CompanyWebsite": "https://polaryx.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Seed",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "Undisclosed",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "Majority shareholder is Mstone Healthcare",
    "FundingNotesLink": "",
    "Commercial stage": "Pivotal stage",
    "RPDD Month": "9",
    "RPDD Date": "2",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Krabbe Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Praxis Precision Medicines",
    "Candidate": "elsunersen (PRAX-222)",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "SCN2A Developmental and Epileptic Encephalopathy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Praxis Precision Medicines",
    "Candidate": "relutrigine (PRAX-562)/SCN2a",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "SCN2A Developmental and Epileptic Encephalopathy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Praxis Precision Medicines",
    "Candidate": "relutrigine (PRAX-562)/SCN8a",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "SCN8A Developmental and Epileptic Encephalopathy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Prometic Life Sciences",
    "Candidate": "RYPLAZIM",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "CA",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2021",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2021",
    "PRV Month": "7",
    "Date": "2",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "Hypoplasminogenemia",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "plasminogen, human-tvmh",
    "Class1": "Enzyme Replacement",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Undisclosed",
    "Sale Price (USD Millions)": "105",
    "Purchase Month": "8",
    "Purchase Date": "9",
    "Purchase Year": "2021",
    "Acquisition": "N",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Protara Therapeutics",
    "Candidate": "TARA-002",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "Lymphatic Malformations",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "PTC Therapeutics",
    "Candidate": "mirdametinib",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "11",
    "RPDD Date": "",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 2b",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "Neurology",
    "Indication": "Neurofibromatosis type 1-associated Plexiform Neurofibromas",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Regeneron Pharmaceuticals",
    "Candidate": "DB-OTO",
    "CompanyWebsite": "",
    "Company 2": "Decibel Therapeutics",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Otolaryngology",
    "TherapeuticArea2": "",
    "Indication": "Otoferlin-Related Congenital Hearing Loss",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Rescindo Therapeutics",
    "Candidate": "RSC-57",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "2",
    "RPDD Date": "12",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "Kabuki Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Retrotope",
    "Candidate": "RT001/FA",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 2/3",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Friedreich Ataxia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Retrotope",
    "Candidate": "RT001/IND",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 2/3",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Infantile Neuroaxonal Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Taysha Gene Therapies",
    "Candidate": "TSHA-105",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2021",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "SLC13A5 Deficiency",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Wellstat",
    "Candidate": "Xuriden",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2021",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2015",
    "PRV Month": "4",
    "Date": "7",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Hereditary orotic aciduria",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "uridine triacetate",
    "Class1": "Analogs & derivatives",
    "Class2": "",
    "Class3": "",
    "MOA": "Pyrimidine analogs",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "AstraZeneca",
    "Sale Price (USD Millions)": "Undisclosed",
    "Purchase Month": "9",
    "Purchase Date": "9",
    "Purchase Year": "2015",
    "Acquisition": "N",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Y-mAbs Therapeutics",
    "Candidate": "lutetium-177(177Lu)-omburtamab-DTPA",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Medulloblastoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Zentalis Pharmaceuticals",
    "Candidate": "ZN-c3",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mid",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2021",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Osteosarcoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Akari Therapeutics",
    "Candidate": "nomacopan",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "UK",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Pivotal stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 3",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "HSCT-related Thrombotic Microangiopathy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Angitia Biopharmaceuticals",
    "Candidate": "AGA2115",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Orthopedics",
    "TherapeuticArea2": "",
    "Indication": "Osteogenesis Imperfecta",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Aptacure Therapeutics",
    "Candidate": "Apc001OA",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "HK",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Orthopedics",
    "TherapeuticArea2": "",
    "Indication": "Osteogenesis Imperfecta",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Aro Biotherapeutics",
    "Candidate": "ABX1100",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Pompe Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Ascentage Pharma",
    "Candidate": "APG-115",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "CN",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Neuroblastoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "AVROBIO",
    "Candidate": "AVR-RD-02",
    "CompanyWebsite": "",
    "Company 2": "Tectonic Therapeutic",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Gaucher Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Belite Bio",
    "Candidate": "tinlarebant",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Pivotal stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 3",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "",
    "Indication": "Stargardt Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "BOOST Pharma",
    "Candidate": "MSC",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "DK",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Orthopedics",
    "TherapeuticArea2": "",
    "Indication": "Osteogenesis Imperfecta",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Caeregen Therapeutics",
    "Candidate": "Noregenâ„¢ (CTR-107)",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "",
    "Indication": "Familial Exudative Vitreoretinopathy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Codexis",
    "Candidate": "CDX-6512",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Homocystinuria",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "DepYmed",
    "Candidate": "PTP1B inhibitor",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Rett Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Editas Medicines",
    "Candidate": "EDIT-301",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "Beta Thalassemia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Eiger Biopharmaceuticals",
    "Candidate": "avexitide",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Endocrinology",
    "TherapeuticArea2": "",
    "Indication": "Congenital Hyperinsulinism",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Eligo Bioscience",
    "Candidate": "EB003",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "FR",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Nephrology",
    "TherapeuticArea2": "",
    "Indication": "Hemolytic Uremic Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Enzyvant",
    "Candidate": "EDG-5506",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "11",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "EXO Biologics",
    "Candidate": "EXOB-001",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "BE",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Pulmonology",
    "TherapeuticArea2": "",
    "Indication": "Bronchopulmonary Dysplasia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Genentech",
    "Candidate": "ELT-001",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Big pharma",
    "RPDD Month": "10",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Cardiovascular",
    "TherapeuticArea2": "",
    "Indication": "Generalized Arterial Calcification of Infancy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Global Blood Therapeutics",
    "Candidate": "GBT021601 (GBT601)",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Acquired",
    "MarketCapRPD": "",
    "MarketCap": "Mid",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "Sickle Cell Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "Y",
    "Acquirer": "Pfizer",
    "Acquisition Price": "$5,400,000,000.00",
    "Acq month": "8",
    "Acq date": "8",
    "Acq year": "2022",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Global Blood Therapeutics",
    "Candidate": "Inclacumab",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Acquired",
    "MarketCapRPD": "",
    "MarketCap": "Mid",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Pivotal stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 3",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "Sickle Cell Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "Y",
    "Acquirer": "Pfizer",
    "Acquisition Price": "$5,400,000,000.00",
    "Acq month": "8",
    "Acq date": "8",
    "Acq year": "2022",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Gyre Therapeutics",
    "Candidate": "CB 4332",
    "CompanyWebsite": "",
    "Company 2": "Catalyst Biosciences",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Mid",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Immunology",
    "TherapeuticArea2": "",
    "Indication": "Complement Factor I Deficiency",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "iECURE",
    "Candidate": "GTP-506",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Ornithine Transcarbamylase Deficiency",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Immix Biopharma",
    "Candidate": "IMX-110",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 1b/2a",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Rhabdomyosarcoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Ionis Pharmaceuticals",
    "Candidate": "ION582",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Angelman Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "N",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Jnana Therapeutics",
    "Candidate": "JNT-517",
    "CompanyWebsite": "",
    "Company 2": "Otsuka Pharmaceutical",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Acquired",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Phenylketonuria",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "Y",
    "Acquirer": "Otsuka Pharmaceutical",
    "Acquisition Price": "$800,000,000.00",
    "Acq month": "9",
    "Acq date": "23",
    "Acq year": "2024",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Kazia Therapeutics",
    "Candidate": "paxalisib/ATRT",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "AU",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "0-10M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Atypical Theratoid/Rabdoid Tumors",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Lantern Pharma",
    "Candidate": "LP-184",
    "CompanyWebsite": "https://www.lanternpharma.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "25-50M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Pre-IND",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Atypical Teratoid Rhabdoid Tumor",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Lu Guo, Institute of Zoology, Chinese Academy of Sciences",
    "Candidate": "AAV Gene Therapy",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "CN",
    "Public/Private": "Non Profit",
    "MarketCapRPD": "",
    "MarketCap": "Government",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Glutaric Aciduria Type I",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "MedPacto",
    "Candidate": "vactosertib",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "KR",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "50-100M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Osteosarcoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Myrtelle",
    "Candidate": "rAAV-Olig001-ASPA",
    "CompanyWebsite": "https://www.cbinsights.com/company/myrtelle/financials",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "$7,490,000.00",
    "LastFundraiseType": "Debt II",
    "Funding type": "",
    "FundraiseDate": "3/20/2025",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "Phase 1/2",
    "CurrentStudyStatus": "Recruiting",
    "Current Study": "https://www.clinicaltrials.gov/study/NCT04833907?intr=rAAV-Olig001-ASPA&rank=1",
    "EstimatedStudyCompletion": "2027-08-31",
    "LastStatusUpdate": "2025-01-08",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Canavan Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "NCATS",
    "Candidate": "AAV9-hPCCA (NCATS-BL0746)",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Non Profit",
    "MarketCapRPD": "",
    "MarketCap": "Government",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Propionic Acidemia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Neurogene",
    "Candidate": "NGN-201",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Micro",
    "Headcount": "",
    "MarketCapRange": "100-250M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Krabbe Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "NeuroNascent",
    "Candidate": "NNI-351",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "Undisclosed",
    "LastFundraiseType": "NIA Grant",
    "Funding type": "",
    "FundraiseDate": "4/12/2023",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "5",
    "RPDD Date": "24",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Fragile X Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Novartis",
    "Candidate": "AVR-RD-04",
    "CompanyWebsite": "",
    "Company 2": "AVROBIO",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "CH",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mega",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Big pharma",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Gastroenterology",
    "TherapeuticArea2": "",
    "Indication": "Cystinosis",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Noveome Biotherapeutics",
    "Candidate": "ST266",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Necrotizing Enterocolitis",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Oncoheroes Biosciences",
    "Candidate": "dovitinib",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Osteosarcoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Radiopharm Theranostics",
    "Candidate": "DUNP19",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "AU",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Osteosarcoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "REGENXBIO",
    "Candidate": "RGX-202",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mid",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "ResVita Bio",
    "Candidate": "RVB-001",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Otolaryngology",
    "TherapeuticArea2": "",
    "Indication": "Netherton Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Sensorion Therapeutics",
    "Candidate": "OTOF-GT",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "FR",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Otoferlin Gene-mediated Hearing Loss",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Stoke Therapeutics",
    "Candidate": "STK-001",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 1/2a",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Dravet Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Synlogic",
    "Candidate": "SYNB1353",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Classical Homocystinuria",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Telix Pharmaceuticals",
    "Candidate": "CycloSam",
    "CompanyWebsite": "",
    "Company 2": "QSAM Biosciences",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "AU",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mid",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Osteosarcoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "TriAct Therapeutics",
    "Candidate": "iniparib",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Pediatric-Type Diffuse High Grade Glioma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Wugen",
    "Candidate": "WU-CART-007",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2022",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Precursor T-lymphoblastic leukemia/lymphoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Advent Therapeutics",
    "Candidate": "Vitamin A palmitate",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "7",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Pulmonology",
    "TherapeuticArea2": "Neonatology",
    "Indication": "Bronchopulmonary Dysplasia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "water miscible vitamin a palmitate",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Arcturus Therapeutics",
    "Candidate": "ARCT-032",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "11",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 1b",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Pulmonology",
    "TherapeuticArea2": "Genetic",
    "Indication": "Cystic Fibrosis",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "Antifibrotics",
    "Class2": "RNA",
    "Class3": "",
    "MOA": "Cystic fibrosis transmembrane conductance regulator expression stimulants",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Arcturus Therapeutics",
    "Candidate": "ARCT-810",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "11",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 1b",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Ornithine Transcarbamylase Deficiency",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "RNA",
    "Class2": "",
    "Class3": "",
    "MOA": "Ornithine carbamoyltransferase expression stimulants",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "AUM Biosciences",
    "Candidate": "AUM302",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "1",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Neuroblastoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "2 ring heterocyclic compounds",
    "Class2": "Antineoplastics",
    "Class3": "Aza compounds",
    "MOA": "1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors; PIM3 protein inhibitors; Proto oncogene protein c pim 1 inhibitors; Proto-oncogene protein pim-2 inhibitors",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "BioMarin",
    "Candidate": "Brineura",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mid",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2017",
    "PRV Month": "4",
    "Date": "27",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Batten Disease",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "cerliponase alfa",
    "Class1": "Enzyme Replacement",
    "Class2": "",
    "Class3": "",
    "MOA": "hydrolytic lysosomal N-terminal tripeptidyl peptidase",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Novartis",
    "Sale Price (USD Millions)": "125",
    "Purchase Month": "11",
    "Purchase Date": "21",
    "Purchase Year": "2017",
    "Acquisition": "N",
    "Acquirer": "NA",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "8/1/11",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "6/1/14",
    "BLA submission": "2/1/17"
  },
  {
    "Company": "Bloom Science",
    "Candidate": "BL-001",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "8",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Dravet Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Bloomsbury Genetic Therapies",
    "Candidate": "BGT-DTDS",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "UK",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "8",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Dopamine Transporter Deficiency Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "AAV",
    "Class2": "AAV2",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Bloomsbury Genetic Therapies",
    "Candidate": "BGT-INAD",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "UK",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "8",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Infantile Neuroaxonal Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "AAV",
    "Class2": "AAV2",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Bloomsbury Genetic Therapies",
    "Candidate": "BGT-NPC",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "UK",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "8",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "Metabolic",
    "Indication": "Niemann-Pick Disease Type C",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "AAV",
    "Class2": "AAV9",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Bloomsbury Genetic Therapies",
    "Candidate": "BGT-OTCD",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "UK",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "8",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Ornithine Transcarbamylase Deficiency",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "AAV",
    "Class2": "AAV2",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Daiichi Sankyo",
    "Candidate": "DS-2325",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "JP",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "5",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Dermatology",
    "TherapeuticArea2": "Genetic",
    "Indication": "Netherton Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Dyne",
    "Candidate": "DYNE-251",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "5",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Edgewise",
    "Candidate": "EDG-5506",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Pubic",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "11",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Elastrin",
    "Candidate": "ELT-001",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "10",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Cardiovascular",
    "TherapeuticArea2": "",
    "Indication": "Generalized Arterial Calcification of Infancy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "FLAG Therapeutics",
    "Candidate": "FLAG-003",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "2",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Diffuse Intrinsic Pontine Glioma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "GC Therapeutics",
    "Candidate": "GC1130A",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "KR",
    "Public/Private": "Pubic",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "1",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "Metabolic",
    "Indication": "Sanfilippo Syndrome A",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Gut-Brain-Axis Therapeutics",
    "Candidate": "Microbiota Transplant Therapy",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "8",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "Genetic",
    "Indication": "Pitt-Hopkins Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "HuidaGene",
    "Candidate": "HG004",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "CN",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "8",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "Genetic",
    "Indication": "RPE65 mutations inherited retinal disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "HuidaGene",
    "Candidate": "HG204",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "CN",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "8",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "Genetic",
    "Indication": "MECP2 duplication syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "HuidaGene",
    "Candidate": "HG302",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "CN",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Ionis Pharmaceuticals",
    "Candidate": "ION356",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "10",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "Genetic",
    "Indication": "Pelizaeus-Merzbacher Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "JCR Pharmaceuticals",
    "Candidate": "JR-141",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "JP",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "1",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 3",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Mucopolysaccharidosis Type II",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Lactiga",
    "Candidate": "LCTG-001",
    "CompanyWebsite": "https://lactiga.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "Undisclosed",
    "LastFundraiseType": "NIH Grant",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "8",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Immunology",
    "TherapeuticArea2": "",
    "Indication": "Common Variable Immunodeficiency",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Laminar Therapeutics",
    "Candidate": "LAM561",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "$6,300,000.00",
    "LastFundraiseType": "B",
    "Funding type": "",
    "FundraiseDate": "2/25/2025",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "9",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Diffuse High Grade Glioma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Mirum Pharmaceuticals",
    "Candidate": "LIVMARLI",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mid",
    "Headcount": "",
    "MarketCapRange": "1-10B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2024",
    "PRV Month": "8",
    "Date": "28",
    "TherapeuticArea1": "Gastroenterology",
    "TherapeuticArea2": "",
    "Indication": "Alagille syndrome (ALGS)",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "maralixibat",
    "Class1": "Biologic",
    "Class2": "",
    "Class3": "",
    "MOA": "Ileal bile acid transporter (IBAT) inhibitor",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Undisclosed",
    "Sale Price (USD Millions)": "110",
    "Purchase Month": "11",
    "Purchase Date": "17",
    "Purchase Year": "2021",
    "Acquisition": "N",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Myopax",
    "Candidate": "Stem Cell Therapy",
    "CompanyWebsite": "https://myopax.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "DE",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "$500,000.00",
    "LastFundraiseType": "Seed",
    "Funding type": "",
    "FundraiseDate": "5/6/2024",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "7",
    "RPDD Date": "10",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Urology",
    "TherapeuticArea2": "",
    "Indication": "Exstrophy-Epispadias-Complex",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "NorthSea Therapeutics",
    "Candidate": "SEFA-6179",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "NL",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "10",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 2a",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Gastroenterology",
    "TherapeuticArea2": "Hepatology",
    "Indication": "Intestinal Failure-Associated Liver Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Ocugen",
    "Candidate": "OCU410ST",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "4",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "Genetic",
    "Indication": "Stargardt Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Origin",
    "Candidate": "NULIBRY",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2021",
    "PRV Month": "3",
    "Date": "12",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Molybdenum Cofactor Deficiency Type A",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "fosdenopterin",
    "Class1": "Enzyme Replacement",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Undisclosed",
    "Sale Price (USD Millions)": "110",
    "Purchase Month": "5",
    "Purchase Date": "13",
    "Purchase Year": "2022",
    "Acquisition": "N",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "PTC",
    "Candidate": "Kebilidi",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2024",
    "PRV Month": "11",
    "Date": "14",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "aromatic L-amino acid decarboxylase deficiency",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "eladocagene exuparvovec-tneq",
    "Class1": "Gene therapy",
    "Class2": "",
    "Class3": "",
    "MOA": "Anti-infllamatory corticosteroid",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Undisclosed",
    "Sale Price (USD Millions)": "150",
    "Purchase Month": "11",
    "Purchase Date": "26",
    "Purchase Year": "2024",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Satellos",
    "Candidate": "SAT-3153",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "CA",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "8",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Sernova",
    "Candidate": "Cell Pouch",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "CA",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "11",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "Hemophilia Type A",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "SiSaf",
    "Candidate": "SIS-101-ADO",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "UK",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "5",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "Metabolic",
    "Indication": "Osteopetrosis",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "SpringWorks",
    "Candidate": "mirdametinib",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "11",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 2b",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "Neurology",
    "Indication": "Neurofibromatosis type 1-associated Plexiform Neurofibromas",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Sumitomo",
    "Candidate": "TP-1287",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "JP",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "4",
    "RPDD Date": "11",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Ewing's Sarcoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "CDK9 inhibitor",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "SynaptixBio",
    "Candidate": "SB-19642",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "UK",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "2",
    "RPDD Date": "9",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Phase 1",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "TUBB4A Leukodystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Synlogic",
    "Candidate": "labafenogene marselecobac (SYNB1934)",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Pivotal stage",
    "RPDD Month": "1",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Phase 3",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Phenylketonuria",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Takeda",
    "Candidate": "ADZYNMA",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "JP",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mega",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "3",
    "RPDD Date": "3",
    "RPDD Year": "2023",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2024",
    "PRV Month": "1",
    "Date": "11",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "Congenital Thrombotic Thrombocytopenic Purpura",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "Enzyme Replacement",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": " (RPD-2022-685)",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "9/5/08",
    "FTD granted": "2/17/17",
    "RPDD granted": "3/3/23",
    "BLA submission": "#N/A"
  },
  {
    "Company": "Tetra (Shionogi)",
    "Candidate": "zatolmilast",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "JP",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "9",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "Genetic",
    "Indication": "Fragile X Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "TBD",
    "Class2": "TBD",
    "Class3": "TBD",
    "MOA": "TBD",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "X4 Pharmaceuticals",
    "Candidate": "Xolremdi",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "12",
    "RPDD Date": "",
    "RPDD Year": "2023",
    "Current Development Stage": "PRV Awarded",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2024",
    "PRV Month": "5",
    "Date": "16",
    "TherapeuticArea1": "Immunology",
    "TherapeuticArea2": "",
    "Indication": "WHIM Syndrome",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "mavorixafor",
    "Class1": "Pharmacotherapies",
    "Class2": "",
    "Class3": "",
    "MOA": "CXC chemokine receptor 4 antagonist",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Undisclosed",
    "Sale Price (USD Millions)": "105",
    "Purchase Month": "5",
    "Purchase Date": "9",
    "Purchase Year": "2024",
    "Acquisition": "N",
    "Acquirer": "NA",
    "Acquisition Price": "NA",
    "Acq month": "NA",
    "Acq date": "NA",
    "Acq year": "NA",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "4D Molecular Therapeutics",
    "Candidate": "4D-710",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Pulmonology",
    "TherapeuticArea2": "",
    "Indication": "Cystic Fibrosis",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Actio Biosciences",
    "Candidate": "ABS-0871",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Charcot-Marie-Tooth Disease",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Actuate Therapeutics",
    "Candidate": "Elraglusib",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "IE",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Ewing's Sarcoma",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Alkeus Pharmaceuticals",
    "Candidate": "gildeuretinol (ALK-001)",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "",
    "Indication": "Stargardt Disease",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "AlveoGene",
    "Candidate": "AVG-002",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "UK",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Pulmonology",
    "TherapeuticArea2": "",
    "Indication": "Surfactant Protein B Deficiency",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Aptacure Therapeutics",
    "Candidate": "Apc001",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "HK",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Endocrinology",
    "TherapeuticArea2": "",
    "Indication": "X-linked Hypophosphatemia",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "9/5/08",
    "FTD granted": "2/17/17",
    "RPDD granted": "3/3/23",
    "BLA submission": "#N/A"
  },
  {
    "Company": "Argenica Therapeutics",
    "Candidate": "ARG-006",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "AU",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Hypoxic Ischaemic Encephalopathy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Argenica Therapeutics",
    "Candidate": "ARG-007",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "AU",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Hypoxic Ischaemic Encephalopathy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "ARTHex Biotech",
    "Candidate": "ATX-01",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "SP",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1/2a",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Myotonic Dystrophy Type 1",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Ascidian Therapeutics",
    "Candidate": "ACDN-01",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "",
    "Indication": "Stargardt Disease",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Äshibio",
    "Candidate": "andecaliximab",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Orthopedics",
    "TherapeuticArea2": "",
    "Indication": "Fibrodysplasia Ossificans Progressiva",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "AskBio (Bayer)",
    "Candidate": "AB-1003",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Limb-Girdle Muscular Dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Atamyo Therapeutics",
    "Candidate": "ATA-100",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "FR",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "12",
    "RPDD Date": "13",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "Neurology",
    "Indication": "Limb-Girdle Muscular Dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "Adeno-Associated Virus serotype 9",
    "Class1": "Gene therapy",
    "Class2": "Adeno-associated viral vectors",
    "Class3": "",
    "MOA": "Adeno-associated virus serotype 9",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "9/5/2023",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "12/13/2024",
    "BLA submission": ""
  },
  {
    "Company": "Atamyo Therapeutics",
    "Candidate": "ATA-200",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "FR",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "11",
    "RPDD Date": "19",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1 ready",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Limb-Girdle Muscular Dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Atsena Therapeutics",
    "Candidate": "ATSN-101",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "",
    "Indication": "GUCY2D-associated Leber Congenital Amaurosis",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Atsena Therapeutics",
    "Candidate": "ATSN-201",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "",
    "Indication": "X-linked Retinoschisis",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Avidity Biosciences",
    "Candidate": "AOC 1044",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Biohaven",
    "Candidate": "taldefgrobep alfa",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Pivotal stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 3",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Spinal Muscular Atrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "BPGbio",
    "Candidate": "BPM31510IV",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Primary Coenzyme Q10 (CoQ10) Deficiency",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "BPGbio",
    "Candidate": "BPM31510T",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Dermatology",
    "TherapeuticArea2": "",
    "Indication": "Epidermolysis Bullosa",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "BridgeBio",
    "Candidate": "BBP-418",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 3",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Limb-Girdle Muscular Dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Cabaletta Bio",
    "Candidate": "CABA-201",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Rheumatology",
    "TherapeuticArea2": "",
    "Indication": "Juvenile Dermatomyositis",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "CAMP4 Therapeutics",
    "Candidate": "CMP-CPS-001",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Urea Cycle Disorders",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Cartesian Therapeutics",
    "Candidate": "Descartes-08",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 2 planned",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Rheumatology",
    "TherapeuticArea2": "",
    "Indication": "Juvenile Dermatomyositis",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Cellectis",
    "Candidate": "UCART22",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "FR",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "Hematology",
    "Indication": "Acute Lymphoblastic Leukemia",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "ChromaDex",
    "Candidate": "nicotinamide adenine dinucleotide",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Ataxia Telangiectasia",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Coave Therapeutics",
    "Candidate": "HORA-PDE6b",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "FR",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "",
    "Indication": "PDE6b-related Retinitis Pigmentosa",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "ConSynance Therapeutics",
    "Candidate": "CSTI-500",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 2-ready",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Endocrinology",
    "TherapeuticArea2": "",
    "Indication": "Prader-Willi Syndrome",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Cumberland Pharmaceuticals",
    "Candidate": "Ifetroban",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "TOBI; Cayston; Pulomzyme",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Disc Medicine",
    "Candidate": "Bitopertin",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "Erythropoietic Porphyrias",
    "Approved Drug": "Y",
    "FDA-Approved Therapy Prior to 2012": "TOBI; Cayston; Pulomzyme",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Dr. Noah Biotech",
    "Candidate": "NDC-026",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "KR",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Drug Farm",
    "Candidate": "DF-003",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "ROSAH Syndrome",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Elixirgen Therapeutics",
    "Candidate": "EXG-34217",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "Dyskeratosis Congenita",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Elpida Therapeutics",
    "Candidate": "Elpida-02",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Charcot-Marie-Tooth Disease",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Enterprise Therapeutics",
    "Candidate": "ETD001",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "UK",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 2a",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Pulmonology",
    "TherapeuticArea2": "",
    "Indication": "Cystic Fibrosis",
    "Approved Drug": "Y",
    "FDA-Approved Therapy Prior to 2012": "Arranon; Clolar",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "GN Corporation",
    "Candidate": "Neu REFIX Beta glucan",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "JP",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "Felbatol; Onfi; Lamictal; Topamax; Banzel",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Hollenbeck Pharmaceuticals",
    "Candidate": "HOL-101 (Growth Hormone Releasing Hormone 1-44 amide)",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Endocrinology",
    "TherapeuticArea2": "",
    "Indication": "Growth Hormone Deficiency",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "Small molecules",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Ilya Pharma",
    "Candidate": "emilimogene sigulactibac",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "SE",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Immunology",
    "TherapeuticArea2": "",
    "Indication": "STING-associated Vasculopathy with Onset in Infancy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Imaging Biometrics",
    "Candidate": "IB-003",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Atypical Teratoid/Rhabdoid Tumor",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Imaging Biometrics",
    "Candidate": "IB-003",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Diffuse High Grade Glioma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "Small molecules",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "ImmuneSensor Therapeutics",
    "Candidate": "IMSB301",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Aicardi GoutiÃ¨res Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "INmune Bio",
    "Candidate": "CORDStrom",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Pivotal stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 3",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Dermatology",
    "TherapeuticArea2": "",
    "Indication": "Recessive Dystrophic Epidermolysis Bullosa",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Innorna",
    "Candidate": "IN022",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "CN",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Homocystinuria",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Invenra",
    "Candidate": "INV724",
    "CompanyWebsite": "https://invenra.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "$7,000,000.00",
    "LastFundraiseType": "B",
    "Funding type": "",
    "FundraiseDate": "10/22/2018",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Neuroblastoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Jaguar Gene Therapy",
    "Candidate": "JAG201",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "$139,000,000.00",
    "LastFundraiseType": "B",
    "Funding type": "",
    "FundraiseDate": "4/13/2021",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Phelan-McDermid syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Krystal Biotech",
    "Candidate": "KB707",
    "CompanyWebsite": "https://www.krystalbio.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "1-10B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Osteosarcoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Lantern Pharma",
    "Candidate": "LP-184",
    "CompanyWebsite": "https://www.lanternpharma.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "25-50M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "9",
    "RPDD Date": "23",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Pre-IND",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Malignant Rhabdoid Tumors",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Lantern Pharma",
    "Candidate": "LP-184",
    "CompanyWebsite": "https://www.lanternpharma.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "25-50M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Pre-IND",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Rhabdomyosarcoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Lisata Therapeutics",
    "Candidate": "LSTA1",
    "CompanyWebsite": "www.lisata.com",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "10-25M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "3",
    "RPDD Date": "21",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Osteosarcoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "certepetide",
    "Class1": "bifunctional cyclic peptide",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Lundbeck Pharma",
    "Candidate": "bexicaserin (LP352)",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "DK",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "1-10B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Dravet Syndrome",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "MAIA Biotechnology",
    "Candidate": "THIO",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "25-50M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Diffuse High Grade Glioma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Medivir",
    "Candidate": "MIV-711",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "SE",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "10-25M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Orthopedics",
    "TherapeuticArea2": "",
    "Indication": "Legg-CalvÃ©-Perthes Disease",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "MeiraGTx",
    "Candidate": "AAV5-RDH12",
    "CompanyWebsite": "https://meiragtx.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "UK",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "500M-1B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "",
    "Indication": "RDH12-associated Retinal Dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "MeiraGTx",
    "Candidate": "AAV8-RK-AIPL1",
    "CompanyWebsite": "https://meiragtx.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "UK",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "500M-1B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Pivotal stage",
    "RPDD Month": "1",
    "RPDD Date": "22",
    "RPDD Year": "2024",
    "Current Development Stage": "Pivotal",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "",
    "Indication": "Leber Congenital Amaurosis Type 4",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Merlin Biotech",
    "Candidate": "MER-101",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "$100,000.00",
    "LastFundraiseType": "Donation/grant",
    "Funding type": "",
    "FundraiseDate": "2/11/2025",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "9",
    "RPDD Date": "2",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Ewing's Sarcoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Mesoblast",
    "Candidate": "Revascor",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "AU",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Mid",
    "Headcount": "",
    "MarketCapRange": "1-10B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "1",
    "RPDD Date": "19",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Cardiology",
    "TherapeuticArea2": "",
    "Indication": "Hypoplastic Left Heart Syndrome",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "META Pharmaceuticals",
    "Candidate": "META-001-PH",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "CN",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Micro",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "$15,000,000.00",
    "LastFundraiseType": "Seed",
    "Funding type": "",
    "FundraiseDate": "6/13/2022",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "8",
    "RPDD Date": "7",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Nephrology",
    "TherapeuticArea2": "",
    "Indication": "Primary Hyperoxaluria",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "Small molecules",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Modalis Therapeutics",
    "Candidate": "MDL-101",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "JP",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "25-50M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Congenital Muscular Dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Muscular Dystrophy Association",
    "Candidate": "Choline Acetyltransferase Gene (CHAT)GT",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Non Profit",
    "MarketCapRPD": "",
    "MarketCap": "Advocacy",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Congenital Myasthenic Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "MyoGene Bio",
    "Candidate": "MyoDys45-55",
    "CompanyWebsite": "",
    "Company 2": "https://www.myogenebio.com/home",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "Undisclosed",
    "LastFundraiseType": "Seed",
    "Funding type": "",
    "FundraiseDate": "5/11/2023",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "NCATS",
    "Candidate": "AAV-NPHP5",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Non Profit",
    "MarketCapRPD": "",
    "MarketCap": "Government",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "10",
    "RPDD Date": "18",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "",
    "Indication": "NPHPR mutation-associated Retinal Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "NCATS",
    "Candidate": "AAV5-CNGB1",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Non Profit",
    "MarketCapRPD": "",
    "MarketCap": "Government",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "10",
    "RPDD Date": "18",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "",
    "Indication": "Autosomal Recessive Retinitis Pigmentosa due to CNGB1 Mutation",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "NCATS",
    "Candidate": "AAV8-hGALNS",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Non Profit",
    "MarketCapRPD": "",
    "MarketCap": "Government",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "10",
    "RPDD Date": "18",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Mucopolysaccharidosis IVA",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "NCATS",
    "Candidate": "AAV8-hSLC4A11",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Non Profit",
    "MarketCapRPD": "",
    "MarketCap": "Government",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "10",
    "RPDD Date": "18",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "",
    "Indication": "Congenital Hereditary Endothelial Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "NCATS",
    "Candidate": "AAV9-hPCCB",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Non Profit",
    "MarketCapRPD": "",
    "MarketCap": "Government",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "10",
    "RPDD Date": "18",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Propionic Acidemia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "NCATS",
    "Candidate": "AAV9-SUMF1",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Non Profit",
    "MarketCapRPD": "",
    "MarketCap": "Government",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "10",
    "RPDD Date": "18",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Multiple Sulfatase Deficiency",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Neuren Pharmaceuticals",
    "Candidate": "NNZ-2591/PM",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "AU",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "500M-1B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Phelan-McDermid Syndrome",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Nobias Therapeutics",
    "Candidate": "NB-001",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "$6,000,000.00",
    "LastFundraiseType": "A/B",
    "Funding type": "",
    "FundraiseDate": "1/1/2024",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "12",
    "RPDD Date": "5",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Immunology",
    "TherapeuticArea2": "",
    "Indication": "DiGeorge Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "NS Pharma",
    "Candidate": "brogidirsen (NS-089/NCNP-02)",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "JP",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "NS Pharma",
    "Candidate": "NS-050/NCNP-03",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "JP",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Ocuphire Pharma",
    "Candidate": "OPGx-LCA5",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "",
    "Indication": "Leber Congenital Amaurosis 5",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Omeros",
    "Candidate": "zaltenibart (OMS906)",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Nephrology",
    "TherapeuticArea2": "",
    "Indication": "Complement 3 Glomerulopathy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Papillon Therapeutics",
    "Candidate": "PPL-001",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Friedreich Ataxia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Papillon Therapeutics",
    "Candidate": "PPL-002",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Cardiology",
    "TherapeuticArea2": "",
    "Indication": "Danon Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "PepGen",
    "Candidate": "PGN-EDO51",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "PIF Partners",
    "Candidate": "101-PGC-005 (â€˜005)",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "IL",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 2-ready",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Rheumatology",
    "TherapeuticArea2": "",
    "Indication": "Systemic Juvenile Idiopathic Arthritis",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Praxis Precision Medicines",
    "Candidate": "relutrigine (PRAX-562)/DS",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Dravet Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "PYC Therapeutics",
    "Candidate": "PYC-001",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "AU",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1-ready",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "",
    "Indication": "Autosomal Dominant Optic Atrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Race Oncology",
    "Candidate": "RC220 bisantrene",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "AU",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "Hematology",
    "Indication": "Acute Myeloid Leukemia",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Ractigen Therapeutics",
    "Candidate": "RAG-18",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "CN",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Safi Bio",
    "Candidate": "Stem-cell derived, human red blood cell (RBC)",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Hematology",
    "TherapeuticArea2": "",
    "Indication": "Sickle Cell Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Saol Therapeutics",
    "Candidate": "SL-1009",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Filed",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "",
    "Indication": "Pyruvate Dehydrogenase Complex Deficiency",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Satellos",
    "Candidate": "SAT-3247",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "CA",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "SELLAS Life Sciences",
    "Candidate": "Galinpepimut-S",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Pivotal stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 3",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "Hematology",
    "Indication": "Acute Myeloid Leukemia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "SELLAS Life Sciences",
    "Candidate": "SLS009-ALL",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "6",
    "RPDD Date": "24",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "Hematology",
    "Indication": "Acute Lymphoblastic Leukemia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "SELLAS Life Sciences",
    "Candidate": "SLS009-AML",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "7",
    "RPDD Date": "16",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "Hematology",
    "Indication": "Acute Myeloid Leukemia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Senhwa Biosciences",
    "Candidate": "silmitasertib/NB",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "TW",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1-ready",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Neuroblastoma",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Siren Biotechnology",
    "Candidate": "SRN-101",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Diffuse High Grade Glioma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Solid Biosciences",
    "Candidate": "SGT-003",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Somite Therapeutics",
    "Candidate": "SMT-M01",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Tenaya Therapeutics",
    "Candidate": "TN-201",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1b",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Cardiology",
    "TherapeuticArea2": "",
    "Indication": "MYBPC3-associated Hypertrophic Cardiomyopathy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Theriva Biologics",
    "Candidate": "VCN-01",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Retinoblastoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Tonix Pharmaceuticals",
    "Candidate": "TNX-2900",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Endocrinology",
    "TherapeuticArea2": "",
    "Indication": "Prader-Willi Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Tyre Biosciences",
    "Candidate": "TYRA-300",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Orthopedics",
    "TherapeuticArea2": "",
    "Indication": "Achondroplasia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Wave Life Sciences",
    "Candidate": "WVE-N531",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "8",
    "RPDD Date": "20",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1/2",
    "PRV Status": "Phase 2",
    "CurrentStudyStatus": "Results Announced",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "3/26/2025",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "TBD",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "YolTech",
    "Candidate": "YOLT-203",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "CN",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Nephrology",
    "TherapeuticArea2": "",
    "Indication": "Primary Hyperoxaluria Type 1",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Zevra Therapeutics",
    "Candidate": "Miplyffa",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2024",
    "Current Development Stage": "Phase 3",
    "PRV Status": "PRV Awarded",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "2024",
    "PRV Month": "10",
    "Date": "8",
    "TherapeuticArea1": "Metabolic",
    "TherapeuticArea2": "Neurology",
    "Indication": "Niemann-Pick disease type C",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "N",
    "Active Ingredient": "Arimoclomol",
    "Class1": "Small Molecule",
    "Class2": "",
    "Class3": "",
    "MOA": "Organic Cation Transporter 2 Inhibitor",
    "Redeemed": "",
    "Purchased": "Y",
    "Purchaser": "Undisclosed",
    "Sale Price (USD Millions)": "150",
    "Purchase Month": "2",
    "Purchase Date": "27",
    "Purchase Year": "2025",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Arbor Biotechnologies",
    "Candidate": "ABO-101",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2025",
    "Current Development Stage": "Phase 1/2-ready",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Primary Hyperoxaluria Type 1",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Ensoma",
    "Candidate": "EN-374",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2025",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Gastroenterology",
    "TherapeuticArea2": "",
    "Indication": "X-linked Chronic Granulomatous Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "MeiraGTx",
    "Candidate": "AAV8-RK-BBS10",
    "CompanyWebsite": "https://meiragtx.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "UK",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "500M-1B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2025",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "",
    "Indication": "Bardet-Biedl Syndrome due to BBS10 mutations",
    "Approved Drug": "N",
    "FDA-Approved Therapy Prior to 2012": "None",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "MeiraGTx",
    "Candidate": "AAV8-RK-RetGC",
    "CompanyWebsite": "https://meiragtx.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "UK",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "500M-1B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "1",
    "RPDD Date": "22",
    "RPDD Year": "2025",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "",
    "Indication": "Leber Congenital Amaurosis",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Neuren Pharmaceuticals",
    "Candidate": "NNZ-2591/AS",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "AU",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "500M-1B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2025",
    "Current Development Stage": "Phase 2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Immunology",
    "TherapeuticArea2": "",
    "Indication": "Angelman Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Neuren Pharmaceuticals",
    "Candidate": "NNZ-2591/PHS",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "AU",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "500M-1B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2025",
    "Current Development Stage": "Phase 2",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Pitt-Hopkins Syndrome",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Neurenati Therapeutics",
    "Candidate": "NEU-001",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "CA",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "500M-1B",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2025",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Nephrology",
    "TherapeuticArea2": "",
    "Indication": "Hirschsprung Disease",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "NS Pharma",
    "Candidate": "NS-051/NCNP-04",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "JP",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Large",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Commercial stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2025",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neuromuscular",
    "TherapeuticArea2": "",
    "Indication": "Duchenne Muscular Dystrophy",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "PYC Therapeutics",
    "Candidate": "VP-001",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "AU",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Clinical stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2025",
    "Current Development Stage": "Phase 1",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "",
    "Indication": "Retinitis Pigmentosa",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Seed Therapeutics",
    "Candidate": "ST-01156",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2025",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Pediatric oncology",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Tikun Therapeutics",
    "Candidate": "BPN-36964",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2025",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Neurology",
    "TherapeuticArea2": "",
    "Indication": "Familial Dysautonomia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Tikun Therapeutics",
    "Candidate": "rAAV2-U1a-hELP1",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2025",
    "Current Development Stage": "Preclinical",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "",
    "Indication": "Optic Neuropathy in Familial Dysautonomia",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "ViGeneron",
    "Candidate": "VG901",
    "CompanyWebsite": "",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "DE",
    "Public/Private": "Private",
    "MarketCapRPD": "",
    "MarketCap": "Small",
    "Headcount": "",
    "MarketCapRange": "",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "2025",
    "Current Development Stage": "Phase 1b",
    "PRV Status": "",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Ophthalmology",
    "TherapeuticArea2": "",
    "Indication": "Retinitis Pigmentosa",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
    "Company": "Lantern Pharma",
    "Candidate": "LP-184",
    "CompanyWebsite": "https://www.lanternpharma.com/",
    "Company 2": "",
    "Company 2 Context": "",
    "Company 3": "",
    "Company 3 Context": "",
    "COUNTRY": "US",
    "Public/Private": "Public",
    "MarketCapRPD": "",
    "MarketCap": "Nano",
    "Headcount": "",
    "MarketCapRange": "25-50M",
    "TotalFunding": "",
    "LastFundraise": "",
    "LastFundraiseType": "",
    "Funding type": "",
    "FundraiseDate": "",
    "FundingNotes": "",
    "FundingNotesLink": "",
    "Commercial stage": "Early stage",
    "RPDD Month": "",
    "RPDD Date": "",
    "RPDD Year": "",
    "Current Development Stage": "Preclinical",
    "PRV Status": "Pre-IND",
    "CurrentStudyStatus": "",
    "Current Study": "",
    "EstimatedStudyCompletion": "",
    "LastStatusUpdate": "",
    "StatusNote": "",
    "StatusNoteLink": "",
    "PRV Year": "",
    "PRV Month": "",
    "Date": "",
    "TherapeuticArea1": "Oncology",
    "TherapeuticArea2": "",
    "Indication": "Hepatoblastoma",
    "Approved Drug": "",
    "FDA-Approved Therapy Prior to 2012": "",
    "Active Ingredient": "",
    "Class1": "",
    "Class2": "",
    "Class3": "",
    "MOA": "",
    "Redeemed": "",
    "Purchased": "",
    "Purchaser": "",
    "Sale Price (USD Millions)": "",
    "Purchase Month": "",
    "Purchase Date": "",
    "Purchase Year": "",
    "Acquisition": "",
    "Acquirer": "",
    "Acquisition Price": "",
    "Acq month": "",
    "Acq date": "",
    "Acq year": "",
    "Acq notes": "",
    "AssetAcq": "",
    "AssetAcquirer": "",
    "AssetAcqPrice": "",
    "AssetAcqDate": "",
    "IND submission": "",
    "ODD granted": "",
    "FTD granted": "",
    "RPDD granted": "",
    "BLA submission": ""
  },
  {
  "Company": "NeOnc Technologies Holdings",
  "Candidate": "NEO100",
  "CompanyWebsite": "https://neonc.com/",
  "Company 2": "",
  "Company 2 Context": "",
  "Company 3": "",
  "Company 3 Context": "",
  "COUNTRY": "US",
  "Public/Private": "Public",
  "MarketCapRPD": "Micro",
  "MarketCap": "Micro",
  "Headcount": "",
  "MarketCapRange": "250-500M",
  "TotalFunding": "",
  "LastFundraise": "",
  "LastFundraiseType": "",
  "Funding type": "",
  "FundraiseDate": "",
  "FundingNotes": "",
  "FundingNotesLink": "",
  "Commercial stage": "Clinical stage",
  "RPDD Month": "3",
  "RPDD Date": "31",
  "RPDD Year": "2025",
  "Current Development Stage": "Phase 2",
  "PRV Status": "",
  "CurrentStudyStatus": "",
  "Current Study": "",
  "EstimatedStudyCompletion": "",
  "LastStatusUpdate": "",
  "StatusNote": "",
  "StatusNoteLink": "",
  "PRV Year": "",
  "PRV Month": "",
  "Date": "",
  "TherapeuticArea1": "Oncology",
  "TherapeuticArea2": "",
  "Indication": "diffuse high-grade gliomas",
  "Approved Drug": "",
  "FDA-Approved Therapy Prior to 2012": "",
  "Active Ingredient": "",
  "Class1": "",
  "Class2": "",
  "Class3": "",
  "MOA": "",
  "Redeemed": "",
  "Purchased": "",
  "Purchaser": "",
  "Sale Price (USD Millions)": "",
  "Purchase Month": "",
  "Purchase Date": "",
  "Purchase Year": "",
  "Acquisition": "",
  "Acquirer": "",
  "Acquisition Price": "",
  "Acq month": "",
  "Acq date": "",
  "Acq year": "",
  "Acq notes": "",
  "AssetAcq": "",
  "AssetAcquirer": "",
  "AssetAcqPrice": "",
  "AssetAcqDate": "",
  "IND submission": "",
  "ODD granted": "",
  "FTD granted": "",
  "RPDD granted": "",
  "BLA submission": ""
}
]